WebCPC CPC COOPERATIVE PATENT CLASSIFICATION

C12N　MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF (biocides, pest repellants or attractants, or plant growth regulators, containing micro-organisms, viruses, microbial fungi, enzymes, fermentates or substances produced by or extracted from micro-organisms or animal material A01N 63/00; food compositions

C12N 1/00 Micro-organisms, e.g. protozoa; Compositions thereof (medicinal preparations containing material from micro-organisms A61K 35/66; preparing medicinal bacterial antigen or antibody compositions, e.g. bacterial vaccines A61K 39/00); Processes of propagating, maintaining or preserving micro-organisms or compositions thereof; Processes of preparing or isolating a composition containing a micro-organism; Culture media therefor

C12N 1/005 ・{after treatment of microbial biomass not covered byC12N 1/02 to C12N 1/08}

C12N 1/02 ・Separating micro-organisms from their culture media

C12N 1/04 ・Preserving or maintaining viable micro-organisms (immobilised micro-organisms C12N 11/00)

C12N 1/06 ・Lysis of micro-organisms

C12N 1/063 ・・{of yeast}

C12N 1/066 ・・{by physical methods}

C12N 1/08 ・Reducing the nucleic acid content

C12N 1/10 ・Protozoa; Culture media therefor

C12N 1/12 ・Unicellular algae; Culture media therefor (culture of multi-cellular plants A01G; as new plants A01H 13/00)

C12N 1/14 ・Fungi (culture of mushrooms A01G 1/04; as new plants per se A01H 15/00; {fungi per se C12R 1/645 to C12R 1/885}) Culture media therefor

C12N 1/16 ・・Yeasts; Culture media therefor

C12N 1/18 ・・・Baker`s yeast; Brewer`s yeast

C12N 1/20 ・Bacteria {(bacteria per se C12R 1/01 to C12R 1/64)}; Culture media therefor

C12N 1/22 ・Processes using, or culture media containing, cellulose or hydrolysates thereof

C12N 1/24 ・Processes using, or culture media containing, waste sulfite liquor

C12N 1/26 ・Processes using, or culture media containing, hydrocarbons (refining of hydrocarbon oils by using micro-organisms C10G 32/00)

C12N 1/28 ・・aliphatic

C12N 1/30 ・・・having five or less carbon atoms

C12N 1/32 ・Processes using, or culture media containing, lower alkanols, i.e. C1 to C6

C12N 1/34 ・Processes using foam culture

C12N 1/36 ・Adaptation or attenuation of cells

C12N 1/38 ・Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound (C12N 1/34 takes precedence)

C12N 3/00 Spore forming or isolating processes

C12N 5/00 Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor; (plant reproduction by tissue culture techniques A01H 4/00)

C12N 5/0012 ・{Cell encapsulation}

C12N 5/0018 ・{Culture media for cell or tissue culture (media for specific animal cell type C12N 5/06)}

C12N 5/0025 ・・{Culture media for plant cell or plant tissue culture}

C12N 5/0031 ・・{Serum-free culture media}

C12N 5/0037 ・・{Serum-free medium, which may still contain naturally-sourced components}

C12N 5/0043 ・・{Medium free of human- or animal-derived components}

C12N 5/005 ・・{Protein-free medium}

C12N 5/0056 ・・{Xeno-free medium}

C12N 5/0062 ・{General methods for three-dimensional culture}

C12N 5/0068 ・{General culture methods using substrates (for specific animal cell type C12N 5/06)}

C12N 5/0075 ・・{using microcarriers}

C12N 5/0081 ・{Purging biological preparations of unwanted cells}

C12N 5/0087 ・・{Purging against subsets of blood cells, e.g. purging alloreactive T cells}

C12N 5/0093 ・・{Purging against cancer cells}

C12N 5/04 ・Plant cells or tissues {(culture media C12N 5/0025)}

C12N 5/06 ・Animal cells or tissues; {Human cells or tissues (preservation of living cells or tissues A01N 1/02); Not used, see subgroups}

C12N 5/0601 ・・{Invertebrate cells or tissues, e.g. insect cells; Culture media therefor}

C12N 5/0602 ・・{Vertebrate cells}

C12N 5/0603 ・・・{Embryonic cells (production of embryos, nuclear transfer A01K 67/027); Embryoid bodies}

C12N 5/0604 ・・・・{Whole embryos; Culture medium therefor}

C12N 5/0605 ・・・・{Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly}

C12N 5/0606 ・・・・{Pluripotent embryonic cells, e.g. embryonic stem cells (ES)(embryonic germ cells C12N 5/0611, induced pluripotent stem cells C12N 5/0696)}

C12N 5/0607 ・・・[N: Non-embryonic pluripotent stem cells, e.g. MASC (induced pluripotent stem cells C12N 5/0696)

C12N 5/0608 ・・・{Germ cells (production of embryos, nuclear transfer A01K 67/027); Not used, see subgroups}

C12N 5/0609 ・・・・{Oocytes, oogonia (fertilised oocytes C12N 5/0604)}

C12N 5/061 ・・・・{Sperm cells, spermatogonia}

C12N 5/0611 ・・・・{Primordial germ cells, e.g. embryonic germ cells (EG)}

C12N 5/0612 ・・・・{sorting of gametes, e.g. according to sex or motility}

C12N 5/0613 ・・・{Cells from endocrine organs (pancreas C12N 5/0676, gonads C12N 5/0681)}

C12N 5/0614 ・・・・{Adrenal gland}

C12N 5/0615 ・・・・{Pineal gland}

C12N 5/0616 ・・・・{Pituitary gland}

C12N 5/0617 ・・・・{Thyroid and parathyroid glands}

C12N 5/0618 ・・・{Cells of the nervous system}

C12N 5/0619 ・・・・{Neurons}

C12N 5/062 ・・・・{Sensory transducers, e.g. photoreceptors; Sensory neurons, e.g. for hearing, taste, smell, pH, touch, temperature, pain}

C12N 5/0621 ・・・・{Eye cells, e.g. cornea, iris pigmented cells (photoreceptors C12N 5/062)}

C12N 5/0622 ・・・・{Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells}

C12N 5/0623 ・・・・{Stem cells}

C12N 5/0625 ・・・{Epidermal cells, skin cells; Cells of the oral mucosa}

C12N 5/0626 ・・・・{Melanocytes}

C12N 5/0627 ・・・・{Hair cells}

C12N 5/0628 ・・・・・{Hair stem cells; Hair progenitors (mesenchymal stem cells from hair follicles C12N 5/0666)}

C12N 5/0629 ・・・・{Keratinocytes; Whole skin}

C12N 5/063 ・・・・・{Kereatinocyte stem cells; Keratinocyte progenitors}

C12N 5/0631 ・・・・{Mammary cells}

C12N 5/0632 ・・・・{Cells of the oral mucosa}

C12N 5/0633 ・・・・{Cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrymal glands}

C12N 5/0634 ・・・{Cells from the blood or the immune system}

C12N 5/0635 ・・・・{B lymphocytes}

C12N 5/0636 ・・・・{T lymphocytes}

C12N 5/0637 ・・・・・{Immunosuppressive T lymphocytes, e.g. regulatory T cells (Treg)}

C12N 5/0638 ・・・・・{Cytotoxic T lymphocytes (CTL), lymphokine activated killer cells (LAK)}

C12N 5/0639 ・・・・{Dendritic cells, e.g. Langherhans cells in the epidermis}

C12N 5/064 ・・・・・{Immunosuppressive dendritic cells}

C12N 5/0641 ・・・・{Erythrocytes}

C12N 5/0642 ・・・・{Granulocytes, e.g. basopils, eosinophils, neutrophils, mast cells}

C12N 5/0643 ・・・・{Osteoclasts}

C12N 5/0644 ・・・・{Platelets; Megakaryocytes}

C12N 5/0645 ・・・・{Macrophages, e.g. Kuepfer cells in the liver; Monocytes}

C12N 5/0646 ・・・・{Natural killers cells (NK), NKT cells}

C12N 5/0647 ・・・・{Haematopoietic stem cells; Uncommited or multipotent progenitors}

C12N 5/0648 ・・・・{Splenocytes}

C12N 5/065 ・・・・{Thymocytes}

C12N 5/0651 ・・・・{Lymph nodes}

C12N 5/0652 ・・・{Cells of skeletal and connective tissues; Mesenchyme}

C12N 5/0653 ・・・・{Adipocytes; Adipose tissue}

C12N 5/0654 ・・・・{Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth}

C12N 5/0655 ・・・・{Chondrocytes; Cartilage}

C12N 5/0656 ・・・・{Adult fibroblasts}

C12N 5/0657 ・・・・{Cardiomyocytes; Heart cells}

C12N 5/0658 ・・・・{Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts}

C12N 5/0659 ・・・・・{Satellite cells}

C12N 5/066 ・・・・{Tenocytes; Tendons, Ligaments}

C12N 5/0661 ・・・・{Smooth muscle cells}

C12N 5/0662 ・・・・{Stem cells}

C12N 5/0663 ・・・・・{Bone marrow mesenchymal stem cells (BM-MSC)}

C12N 5/0664 ・・・・・{Dental pulp stem cells, Dental follicle stem cells}

C12N 5/0665 ・・・・・{Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood}

C12N 5/0666 ・・・・・{Mesenchymal stem cells from hair follicles}

C12N 5/0667 ・・・・・{Adipose-derived stem cells (ADSC); Adipose stromal stem cells}

C12N 5/0668 ・・・・・{Mesenchymal stem cells from other natural sources}

C12N 5/0669 ・・・・{Bone marrow stromal cells; Whole bone marrow (isolated stem cells from bone marrow C12N 5/0647, C12N 5/0663)}

C12N 5/067 ・・・{Hepatocytes}

C12N 5/0671 ・・・・{Three-dimensional culture, tissue culture or organ culture; Encapsulated cells}

C12N 5/0672 ・・・・{Stem cells; Progenitor cells; Precursor cells; Oval cells}

C12N 5/0673 ・・・{Cells from bone marrow stroma}

C12N 5/0675 ・・・・{Mesenchymal stem cells}

C12N 5/0676 ・・・{Pancreatic cells}

C12N 5/0677 ・・・・{Three-dimensional culture, tissue culture or organ culture; Encapsulated cells}

C12N 5/0678 ・・・・{Stem cells; Progenitor cells; Precursor cells}

C12N 5/0679 ・・・{Cells of the gastro-intestinal tract}

C12N 5/068 ・・・・{Stem cells; Progenitors}

C12N 5/0681 ・・・{Cells of the genital tract; Non-germinal cells from gonads; Not used, see subgroups}

C12N 5/0682 ・・・・{Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells (oocytes C12N 5/0609)}

C12N 5/0683 ・・・・{Cells of the male genital tract, e.g. prostate, epididymis; Non-germinal cells from testis, e.g. Leydig cells, Sertoli cells (spermatogonia C12N 5/061)}

C12N 5/0684 ・・・{Cells of the urinary tract or kidneys}

C12N 5/0685 ・・・・{Bladder epithelial cells}

C12N 5/0686 ・・・・{Kidney cells}

C12N 5/0687 ・・・・{Renal stem cells; Renal progenitors}

C12N 5/0688 ・・・{Cells from the lungs or the respiratory tract}

C12N 5/0689 ・・・・{Stem cells; Progenitors}

C12N 5/069 ・・・{Vascular Endothelial cells}

C12N 5/0691 ・・・・{Vascular smooth muscle cells; 3D culture thereof, e.g. models of blood vessels}

C12N 5/0692 ・・・・{Stem cells; Progenitor cells; Precursor cells}

C12N 5/0693 ・・・{Tumour cells; Cancer cells}

C12N 5/0694 ・・・・{Cells of blood, e.g. leukemia cells, myeloma cells}

C12N 5/0695 ・・・・{Stem cells; Progenitor cells; Precursor cells}

C12N 5/0696 ・・・{Artificially induced pluripotent stem cells, e.g. iPS}

C12N 5/0697 ・・{Artificial constructs associating cells of different lineages, e.g. tissue equivalents (blood vessels C12N 5/0691)}

C12N 5/0698 ・・・{Skin equivalents}

C12N 5/10 ・Cells modified by introduction of foreign genetic material {Not used, see subgroups}

C12N 5/12 ・・Fused cells, e.g. hybridomas

C12N 5/14 ・・・Plant cells

C12N 5/16 ・・・Animal cells

C12N 5/163 ・・・・{one of the fusion partners being a B or a T lymphocyte}

C12N 5/166 ・・・・{resulting from interspecies fusion}

C12N 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody composition, e.g. virus vaccines, A61K 39/00)

C12N 7/02 ・Recovery or purification

C12N 7/025 ・・{Packaging cell lines, e.g. transcomplementing cell lines, for production of virus}

C12N 7/04 ・Inactivation or attenuation; Producing viral sub-units

C12N 7/045 ・・{Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered}

C12N 7/06 ・・{Inactivation or attenuation} by chemical treatment

C12N 7/08 ・・{Inactivation or attenuation} by serial passage of virus

C12N 9/00 Enzymes; Proenzymes; Compositions thereof (preparations containing enzymes for cleaning teeth A61K 8/66, A61Q 11/00; medicinal preparations containing enzymes or pro-enzymes A61K 38/43; enzyme containing detergent compositions C11D; {enzymes with nucleic acid structure, e.g. ribozymes, C12N 15/113}); Processes for preparing, activating, inhibiting, separating or purifying enzymes (preparation of malt C12C 1/00)

C12N 9/0002 ・{Antibodies with enzymatic activity; e.g. abzymes}

C12N 9/0004 ・{Oxidoreductases (1.)}

C12N 9/0006 ・・]N: acting on CH-OH groups as donors (1.1)]

C12N 9/0008 ・・{acting on the aldehyde or oxo group of donors (1.2)}

C12N 9/001 ・・{acting on the CH-CH group of donors (1.3)}

C12N 9/0012 ・・{acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)}

C12N 9/0014 ・・・{acting on the CH-NH2 group of donors (1.4)}

C12N 9/0016 ・・・・{with NAD or NADP as acceptor (1.4.1)}

C12N 9/0018 ・・・・・{Phenylalanine dehydrogenase (1.4.1.20)}

C12N 9/002 ・・・・{with a cytochrome as acceptor (1.4.2)}

C12N 9/0022 ・・・・{with oxygen as acceptor (1.4.3)}

C12N 9/0024 ・・・・・{D-Amino acid oxidase (1.4.3.3)}

C12N 9/0026 ・・・{acting on CH-NH groups of donors (1.5)}

C12N 9/0028 ・・・・{with NAD or NADP as acceptor (1.5.1)}

C12N 9/003 ・・・・・{Dihydrofolate reductase (DHFR) (1.5.1.3)}

C12N 9/0032 ・・・・{with oxygen as acceptor (1.5.3)}

C12N 9/0034 ・・・・・{Sarcosine oxidase (1.5.3.1)}

C12N 9/0036 ・・・{acting on NADH or NADPH (1.6)}

C12N 9/0038 ・・・・{with a heme protein as acceptor (1.6.2)}

C12N 9/004 ・・・・・{Cytochrome-b5 reductase (1.6.2.2)}

C12N 9/0042 ・・・・・{NADPH-cytochrome P450 reductase (1.6.2.4)}

C12N 9/0044 ・・・{acting on other nitrogen compounds as donors (1.7)}

C12N 9/0046 ・・・・[N: with oxygen as acceptor (1.7.3)

C12N 9/0048 ・・・・・{Uricase (1.7.3.3)}

C12N 9/0051 ・・{acting on a sulfur group of donors (1.8)}

C12N 9/0053 ・・{acting on a heme group of donors (1.9)}

C12N 9/0055 ・・{acting on diphenols and related substances as donors (1.10)}

C12N 9/0057 ・・・{with oxygen as acceptor (1.10.3)}

C12N 9/0059 ・・・・{Catechol oxidase (1.10.3.1), i.e. tyrosinase}

C12N 9/0061 ・・・・{Laccase (1.10.3.2)}

C12N 9/0063 ・・・・{Ascorbate oxidase (1.10.3.3)}

C12N 9/0065 ・・{acting on hydrogen peroxide as acceptor (1.11)}

C12N 9/0067 ・・{acting on hydrogen as donor (1.12)}

C12N 9/0069 ・・{acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)}

C12N 9/0071 ・・{acting on paired donors with incorporation of molecular oxygen (1.14)}

C12N 9/0073 ・・・{with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13}

C12N 9/0075 ・・・・{Nitric-oxide synthase (1.14.13.39)}

C12N 9/0077 ・・・{with a reduced iron-sulfur protein as one donor (1.14.15)}

C12N 9/0079 ・・・・{Steroid 11 beta monooxygenase (P-450 protein) (1.14.15.4)}

C12N 9/0081 ・・・・{Cholesterol monooxygenase (cytochrome P 450scc) (1.14.15.6)}

C12N 9/0083 ・・・{Miscellaneous (1.14.99)}

C12N 9/0085 ・・・・{Steroid 17 alpha-monooxygenase (1.14.99.9)}

C12N 9/0087 ・・・・{Steroid 21-monooxygenase (1.14.99.10)}

C12N 9/0089 ・・{acting on superoxide as acceptor (1.15)}

C12N 9/0091 ・・{oxidizing metal ions (1.16)}

C12N 9/0093 ・・{acting on CH or CH2 groups (1.17)}

C12N 9/0095 ・・{acting on iron-sulfur proteins as donor (1.18)}

C12N 9/0097 ・・{acting on reduced flavodoxin as donor (1.19)}

C12N 9/10 ・Transferases (2.) (ribonucleases 9/22)

C12N 9/1003 ・・{transferring one-carbon groups (2.1)}

C12N 9/1007 ・・・{Methyltransferases (general) (2.1.1.)}

C12N 9/1011 ・・・・{Catechol O-methyltransferase (2.1.1.6)}

C12N 9/1014 ・・・{Hydroxymethyl-, formyl-transferases (2.1.2)}

C12N 9/1018 ・・・{Carboxy- and carbamoyl transferases (2.1.3)}

C12N 9/1022 ・・{transferring aldehyde or ketonic groups (2.2)}

C12N 9/1025 ・・{Acyltransferases (2.3)}

C12N 9/1029 ・・・{transferring groups other than amino-acyl groups (2.3.1)}

C12N 9/1033 ・・・・{Chloramphenicol O-acetyltransferase (2.3.1.28)}

C12N 9/1037 ・・・・{Naringenin-chalcone synthase (2.3.1.74), i.e. chalcone synthase}

C12N 9/104 ・・・{Aminoacyltransferases (2.3.2)}

C12N 9/1044 ・・・・{Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII}

C12N 9/1048 ・・{Glycosyltransferases (2.4)}

C12N 9/1051 ・・・{Hexosyltransferases (2.4.1)}

C12N 9/1055 ・・・・{Levansucrase (2.4.1.10)}

C12N 9/1059 ・・・・{Cellulose synthases (2.4.1.12; 2.4.1.29)}

C12N 9/1062 ・・・・{Sucrose synthase (2.4.1.13)}

C12N 9/1066 ・・・・{Sucrose phosphate synthase (2.4.1.14)}

C12N 9/107 ・・・・{1,4-Alpha-glucan branching enzyme (2.4.1.18)}

C12N 9/1074 ・・・・{Cyclomaltodextrin glucanotransferase (2.4.1.19)}

C12N 9/1077 ・・・{Pentosyltransferases (2.4.2)}

C12N 9/1081 ・・・{transferring other glycosyl groups (2.4.99)}

C12N 9/1085 ・・{transferring alkyl or aryl groups other than methyl groups (2.5)}

C12N 9/1088 ・・・{Glutathione transferase (2.5.1.18)}

C12N 9/1092 ・・・{3-Phosphoshikimate 1-carboxyvinyltransferase (2.5.1.19), i.e. 5-enolpyruvylshikimate-3-phosphate synthase}

C12N 9/1096 ・・{transferring nitrogenous groups (2.6)}

C12N 9/12 ・・transferring phosphorus containing groups, e.g. kinases (2.7)

C12N 9/1205 ・・・[N: Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases

C12N 9/1211 ・・・・{Thymidine kinase (2.7.1.21)}

C12N 9/1217 ・・・{Phosphotransferases with a carboxyl group as acceptor (2.7.2)}

C12N 9/1223 ・・・{Phosphotransferases with a nitrogenous group as acceptor (2.7.3)}

C12N 9/1229 ・・・{Phosphotransferases with a phosphate group as acceptor (2.7.4)}

C12N 9/1235 ・・・{Diphosphotransferases (2.7.6)}

C12N 9/1241 ・・・{Nucleotidyltransferases (2.7.7)}

C12N 9/1247 ・・・・{DNA-directed RNA polymerase (2.7.7.6)}

C12N 9/1252 ・・・・{DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase}

C12N 9/1258 ・・・・{Polyribonucleotide nucleotidyltransferase (2.7.7.8), i.e. polynucleotide phosphorylase}

C12N 9/1264 ・・・・{DNA nucleotidylexotransferase (2.7.7.31), i.e. terminal nucleotidyl transferase}

C12N 9/127 ・・・・{RNA-directed RNA polymerase (2.7.7.48), i.e RNA replicase}

C12N 9/1276 ・・・・{RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase}

C12N 9/1282 ・・・・{RNA uridylyltransferase (2.7.7.52)}

C12N 9/1288 ・・・{Transferases for other substituted phosphate groups (2.7.8)}

C12N 9/1294 ・・・{Phosphotransferases with paired acceptors (2.7.9)}

C12N 9/13 ・・{transferring sulfur containing groups (2.8)}

C12N 9/14 ・Hydrolases (3)

C12N 9/16 ・・acting on ester bonds (3.1)

C12N 9/18 ・・・Carboxylic ester hydrolases {(3.1.1)}

C12N 9/20 ・・・・Triglyceride splitting, e.g. by means of lipase

C12N 9/22 ・・・Ribonucleases {RNAses, DNAses (catalytic nucleic acids C12N 15/11B)}

C12N 9/24 ・・acting on glycosyl compounds (3.2)

C12N 9/2402 ・・・{hydrolysing O- and S- glycosyl compounds (3.2.1)}

C12N 9/2405 ・・・・{Glucanases}

C12N 9/2408 ・・・・・{acting on alpha -1,4-glucosidic bonds}

C12N 9/2411 ・・・・・・{Amylases}

C12N 9/2414 ・・・・・・・{Alpha-amylase (3.2.1.1.)}

C12N 9/2417 ・・・・・・・・{from microbiological source}

C12N 9/242 ・・・・・・・・・{Fungal source}

C12N 9/2422 ・・・・・・・・{from plant source}

C12N 9/2425 ・・・・・・・{Beta-amylase (3.2.1.2)}

C12N 9/2428 ・・・・・・・{Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase}

C12N 9/2431 ・・・・・・{Beta-fructofuranosidase (3.2.1.26), i.e. invertase}

C12N 9/2434 ・・・・・{acting on beta-1,4-glucosidic bonds}

C12N 9/2437 ・・・・・・{Cellulases (3.2.1.4; 3.2.1.74; 3.2.1.91; 3.2.1.150)}

C12N 9/244 ・・・・・・{Endo-1,3(4)-beta-glucanase (3.2.1.6)}

C12N 9/2442 ・・・・・・{Chitinase (3.2.1.14)}

C12N 9/2445 ・・・・・・{Beta-glucosidase (3.2.1.21)}

C12N 9/2448 ・・・・・・{Licheninase (3.2.1.73)}

C12N 9/2451 ・・・・・{acting on alpha-1,6-glucosidic bonds}

C12N 9/2454 ・・・・・・{Dextranase (3.2.1.11)}

C12N 9/2457 ・・・・・・{Pullulanase (3.2.1.41)}

C12N 9/246 ・・・・・・{Isoamylase (3.2.1.68)}

C12N 9/2462 ・・・・{Lysozyme (3.2.1.17)}

C12N 9/2465 ・・・・{acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)}

C12N 9/2468 ・・・・{acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)}

C12N 9/2471 ・・・・・{Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase}

C12N 9/2474 ・・・・{Hyaluronoglucosaminidase (3.2.1.35), i.e hyaluronidase}

C12N 9/2477 ・・・・{Hemicellulases not provided in a preceding group}

C12N 9/248 ・・・・・{Xylanases}

C12N 9/2482 ・・・・・・{Endo-1,4-beta-xylanase (3.2.1.8)}

C12N 9/2485 ・・・・・・{Xylan endo-1,3-beta-xylosidase (3.2.1.32), i.e. endo-1,3-beta-xylanase }

C12N 9/2488 ・・・・・{Mannanases}

C12N 9/2491 ・・・・・・{Beta-mannosidase (3.2.1.25), i.e. mannanase}

C12N 9/2494 ・・・・・・{Mannan endo-1,4-beta-mannosidase (3.2.1.78), i.e. endo-beta-mannanase}

C12N 9/2497 ・・・{hydrolysing N- glycosyl compounds (3.2.2)}

C12N 9/26 ・・・acting on alpha -1, 4-glucosidic bonds, e.g. hyaluronidase, invertase, amylase

C12N 9/38 ・・・acting on beta-galactose-glycoside bonds, e.g. beta-galactosidase

C12N 9/42 ・・・acting on beta-1, 4-glucosidic bonds, e.g. cellulase

C12N 9/44 ・・・acting on alpha-1, 6-glucosidic bonds, e.g. isoamylase, pullulanase

C12N 9/48 ・・acting on peptide bonds (3.4)

C12N 9/485 ・・・{Exopeptidases (3.4.11-3.4.19)}

C12N 9/50 ・・・Proteinases {Endopeptidases (3.4.21-3.4.25)}

C12N 9/503 ・・・・{derived from viruses}

C12N 9/506 ・・・・・{derived from RNA viruses}

C12N 9/52 ・・・・derived from bacteria

C12N 9/54 ・・・・・bacteria being Bacillus

C12N 9/58 ・・・・derived from fungi

C12N 9/60 ・・・・・from yeast

C12N 9/62 ・・・・・from Aspergillus

C12N 9/63 ・・・・{derived from plants}

C12N 9/64 ・・・・derived from animal tissue

C12N 9/6402 ・・・・・{from non-mammals}

C12N 9/6405 ・・・・・・{not being snakes}

C12N 9/6408 ・・・・・・・{Serine endopeptidases (3.4.21)}

C12N 9/641 ・・・・・・・{Cysteine endopeptidases (3.4.22)}

C12N 9/6413 ・・・・・・・{Aspartic endopeptidases (3.4.23)}

C12N 9/6416 ・・・・・・・{Metalloendopeptidases (3.4.24)}

C12N 9/6418 ・・・・・・{from snakes}

C12N 9/6421 ・・・・・{from mammals}

C12N 9/6424 ・・・・・・{Serine endopeptidases (3.4.21)}

C12N 9/6427 ・・・・・・・{Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)}

C12N 9/6429 ・・・・・・・{Thrombin (3.4.21.5)}

C12N 9/6432 ・・・・・・・{Coagulation factor Xa (3.4.21.6)}

C12N 9/6435 ・・・・・・・{Plasmin (3.4.21.7), i.e. fibrinolysin}

C12N 9/6437 ・・・・・・・{Coagulation factor VIIa (3.4.21.21)}

C12N 9/644 ・・・・・・・{Coagulation factor IXa (3.4.21.22)}

C12N 9/6443 ・・・・・・・{Coagulation factor XIa (3.4.21.27)}

C12N 9/6445 ・・・・・・・{Kallikreins (3.4.21.34; 3.4.21.35)}

C12N 9/6448 ・・・・・・・{Elastases, e.g. pancreatic elastase (3.4.21.36); leukocyte elastase (3.4.31.37)}

C12N 9/6451 ・・・・・・・{Coagulation factor XIIa (3.4.21.38)}

C12N 9/6454 ・・・・・・・{Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases}

C12N 9/6456 ・・・・・・・{Plasminogen activators}

C12N 9/6459 ・・・・・・・・{t-plasminogen activator (3.4.21.68), i.e. tPA}

C12N 9/6462 ・・・・・・・・{u-Plasminogen activator (3.4.21.73), i.e. urokinase}

C12N 9/6464 ・・・・・・・{Protein C (3.4.21.69)}

C12N 9/6467 ・・・・・・・{Granzymes, e.g granzyme A (3.4.21.78); granzyme B (3.4.21.79)}

C12N 9/647 ・・・・・・・{Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups}

C12N 9/6472 ・・・・・・{Cysteine endopeptidases (3.4.22)}

C12N 9/6475 ・・・・・・・{Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)}

C12N 9/6478 ・・・・・・{Aspartic endopeptidases (3.4.23)}

C12N 9/6481 ・・・・・・・{Pepsins (3.4.23.1; 3.4.23.2; 3.4.23.3)}

C12N 9/6483 ・・・・・・・{Chymosin (3.4.23.4), i.e. rennin}

C12N 9/6486 ・・・・・・・{Renin (3.4.23.15)}

C12N 9/6489 ・・・・・・{Metalloendopeptidases (3.4.24)}

C12N 9/6491 ・・・・・・・{Matrix metalloproteases (MMP's), e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)}

C12N 9/6494 ・・・・・・・{Neprilysin (3.4.24.11), i.e. enkephalinase or neutral-endopeptidase 24.11}

C12N 9/6497 ・・・・・・・{Endothelin-converting enzyme (3.4.24.71)}

C12N 9/78 ・・acting on carbon to nitrogen bonds other than peptide bonds (3.5)

C12N 9/80 ・・・acting on amide bonds in linear amides {(3.5.1)}

C12N 9/82 ・・・・Asparaginase {(3.5.1.1)}

C12N 9/84 ・・・・Penicillin amidase {(3.5.1.11)}

C12N 9/86 ・・・acting on amide bonds in cyclic amides, e.g. penicillinase {(3.5.2)}

C12N 9/88 ・Lyases (4.)

C12N 9/90 ・Isomerases (5.)

C12N 9/92 ・・Glucose isomerase {(5.3.1.5; 5.3.1.9; 5.3.1.18)}

C12N 9/93 ・{Ligases (6)}

C12N 9/94 ・Pancreatin

C12N 9/96 ・Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates

C12N 9/98 ・Preparation of granular or free-flowing enzyme compositions (C12N 9/96 takes precedence)

C12N 9/99 ・Enzyme inactivation by chemical treatment

C12N 11/00 Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof

C12N 11/02 ・Enzymes or microbial cells being immobilised on or in an organic carrier

C12N 11/04 ・・entrapped within the carrier, e.g. gel, hollow fibre

C12N 11/06 ・・attached to the carrier via a bridging agent

C12N 11/08 ・・carrier being a synthetic polymer

C12N 11/10 ・・carrier being a carbohydrate

C12N 11/12 ・・・Cellulose or derivative thereof

C12N 11/14 ・Enzymes or microbial cells being immobilised on or in an inorganic carrier

C12N 11/16 ・Enzymes or microbial cells being immobilised on or in a biological cell

C12N 11/18 ・Multi-enzyme systems

C12N 13/00 Treatment of micro-organisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves

C12N 15/00 Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (mutants or genetically engineered micro-organisms, per se C12N 1/00, C12N 5/00, C12N 7/00; new plants per se A01H; plant reproduction by tissue culture techniques A01H 4/00; new animals per se A01K 67/00; use of medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases, gene therapy A61K 48/00)

C12N 15/01 ・Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor

C12N 15/02 ・Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion {(monoclonal antibodies C07K 16/00; apparatus for cell fusion C12M)}

C12N 15/03 ・・Bacteria

C12N 15/04 ・・Fungi

C12N 15/09 ・Recombinant DNA-technology

C12N 15/10 ・・Processes for the isolation, preparation or purification of DNA or RNA (chemical preparation of DNA or RNA C07H 21/00; preparation of non-structural polynucleotides from micro-organisms or with enzymes C12P 19/34)

C12N 15/1003 ・・・{Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor}

C12N 15/1006 ・・・・{by means of a solid support carrier, e.g. particles, polymers}

C12N 15/101 ・・・・・{by chromatography, e.g. electrophoresis, ion-exchange, reverse phase}

C12N 15/1013 ・・・・・{by using magnetic beads}

C12N 15/1017 ・・・・{by filtration, e.g. using filters, frits, membranes}

C12N 15/102 ・・・{Mutagenizing nucleic acids}

C12N 15/1024 ・・・・{In vivo mutagenesis using high mutation rate "mutator" host strains by inserting genetic material, e.g. encoding an error prone polymerase, disrupting a gene for mismatch repair}

C12N 15/1027 ・・・・{by DNA shuffling, e.g. RSR, STEP, RPR}

C12N 15/1031 ・・・・{mutagenesis by gene assembly, e.g. assembly by oligonucleotide extension PCR}

C12N 15/1034 ・・・{Isolating an individual clone by screening libraries}

C12N 15/1037 ・・・・{Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display}

C12N 15/1041 ・・・・{Ribosome/Polysome display, e.g. SPERT, ARM}

C12N 15/1044 ・・・・{Preparation or screening of libraries displayed on scaffold proteins} s

C12N 15/1048 ・・・・{SELEX}

C12N 15/1051 ・・・・{Gene trapping, e.g. exon-, intron-, IRES-, signal sequence-trap cloning, trap vectors}

C12N 15/1055 ・・・・{Protein x Protein interaction, e.g. two hybrid selection}

C12N 15/1058 ・・・・{Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms}

C12N 15/1062 ・・・・{mRNA-Display, e.g. polypeptide and encoding template are connected covalently}

C12N 15/1065 ・・・・{Preparation or screening of tagged libraries, e.g. tagged microorganisms by

C12N 15/1068 ・・・・{Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis (NRPS), DNA/RNA-polymerase mediated polypeptide synthesis}

C12N 15/1072 ・・・・{Differential gene expression library synthesis, e.g. subtracted libraries, differential screening}

C12N 15/1075 ・・・・{by coupling phenotype to genotype, not provided for in other groups of this subclass}

C12N 15/1079 ・・・・{Screening libraries by altering the phenotype or phenotypic trait of the host (reporter assays C12N 15/1086)}

C12N 15/1082 ・・・・{Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors}

C12N 15/1086 ・・・・{Preparation or screening of expression libraries, e.g. reporter assays}

C12N 15/1089 ・・・・{Design, preparation, screening or analysis of libraries using computer algorithms}

C12N 15/1093 ・・・・{General methods of preparing gene libraries, not provided for in other subgroups}

C12N 15/1096 ・・・{cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR}

C12N 15/11 ・・DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H 21/00);{Non-coding nucleic acids having a biological activity}

C12N 15/111 ・・・{General methods applicable to biologically active non-coding nucleic acids}

C12N 15/113 ・・・Non-coding nucleic acids modulating the expression of genes, e.g.antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N 15/8218)}

C12N 15/1131 ・・・・{against viruses}

C12N 15/1132 ・・・・・{against retroviridae, e.g. HIV}

C12N 15/1133 ・・・・・{against herpetoviridae, e.g. HSV}

C12N 15/1135 ・・・・{against oncogenes or tumor suppressor genes}

C12N 15/1136 ・・・・{against growth factors, growth regulators, cytokines, lymphokines or hormones}

C12N 15/1137 ・・・・{against enzymes (viral enzymes C12N 15/1131; receptors C12N 15/1138)}

C12N 15/1138 ・・・・{against receptors or cell surface proteins}

C12N 15/115 ・・・Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith; {Nucleic acids binding to non-nucleic acids, e.g. aptamers}

C12N 15/117 ・・・Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs

C12N 15/52 ・・・Genes encoding for enzymes or proenzymes

C12N 15/62 ・・・DNA sequences coding for fusion proteins

C12N 15/625 ・・・・{containing a sequence coding for a signal sequence}

C12N 15/63 ・・Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

C12N 15/635 ・・・{Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline}

C12N 15/64 ・・・General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host

C12N 15/65 ・・・using markers (enzymes used as markers C12N 15/52)

C12N 15/66 ・・・General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease

C12N 15/67 ・・・General methods for enhancing the expression

C12N 15/68 ・・・・Stabilisation of the vector

C12N 15/69 ・・・・Increasing the copy number of the vector

C12N 15/70 ・・・Vectors or expression systems specially adapted for E. coli

C12N 15/71 ・・・・Expression systems using regulatory sequences derived from the trp-operon

C12N 15/72 ・・・・Expression systems using regulatory sequences derived from the lac-operon

C12N 15/73 ・・・・Expression systems using phage (lambda) regulatory sequences

C12N 15/74 ・・・Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora

C12N 15/743 ・・・・{for Agrobacterium; Rhizobium; Bradyrhizobium}

C12N 15/746 ・・・・{for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)}

C12N 15/75 ・・・・for Bacillus

C12N 15/76 ・・・・for Actinomyces; for Streptomyces

C12N 15/77 ・・・・for Corynebacterium; for Brevibacterium

C12N 15/78 ・・・・for Pseudomonas

C12N 15/79 ・・・Vectors or expression systems specially adapted for eukaryotic hosts

C12N 15/80 ・・・・for fungi

C12N 15/81 ・・・・・for yeasts

C12N 15/815 ・・・・・・{for yeasts other than Saccharomyces}

C12N 15/82 ・・・・for plant cells, {e.g. plant artificial chromosomes (PACs)}

C12N 15/8201 ・・・・・{Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation}

C12N 15/8202 ・・・・・・{by biological means, e.g. cell mediated or natural vector}

C12N 15/8203 ・・・・・・・{Virus mediated transformation}

C12N 15/8205 ・・・・・・・{Agrobacterium mediated transformation}

C12N 15/8206 ・・・・・・{by physical or chemical, i.e. non-biological, means, e.g. electroporation, PEG mediated}

C12N 15/8207 ・・・・・・・{by mechanical means, e.g. microinjection, particle bombardment, silicon whiskers}

C12N 15/8209 ・・・・・・{Selection, visualisation of transformants, reporter constructs, e.g. antibiotic resistance markers}

C12N 15/821 ・・・・・・・{Non-antibiotic resistance markers, e.g. morphogenetic, metabolic markers}

C12N 15/8212 ・・・・・・・・{Colour markers, e.g. beta-glucoronidase (GUS), green fluorescent protein (GFP), carotenoid}

C12N 15/8213 ・・・・・・{Targeted insertion of genes into the plant genome by homologous recombination}

C12N 15/8214 ・・・・・・{Plastid transformation}

C12N 15/8216 ・・・・・{Methods for controlling, regulating or enhancing expression of transgenes in plant cells}

C12N 15/8217 ・・・・・・{Gene switch}

C12N 15/8218 ・・・・・・{Antisense, co-suppression, viral induced gene silencing (VIGS), post-transcriptional induced gene silencing (PTGS)}

C12N 15/822 ・・・・・・{Reducing position variability, e.g. by the use of scaffold attachment region/matrix attachment region (SAR/MAR); Use of SAR/MAR to regulate gene expression}

C12N 15/8221 ・・・・・・{Transit peptides}

C12N 15/8222 ・・・・・・{Developmentally regulated expression systems, tissue, organ specific, temporal or spatial regulation}

C12N 15/8223 ・・・・・・・{Vegetative tissue-specific promoters}

C12N 15/8225 ・・・・・・・・{Leaf-specific, e.g. including petioles, stomata}

C12N 15/8226 ・・・・・・・・{Stem-specific, e.g. including tubers, beets}

C12N 15/8227 ・・・・・・・・{Root-specific}

C12N 15/8229 ・・・・・・・・{Meristem-specific, e.g. nodal, apical}

C12N 15/823 ・・・・・・・{Reproductive tissue-specific promoters}

C12N 15/8231 ・・・・・・・・{Male-specific, e.g. anther, tapetum, pollen}

C12N 15/8233 ・・・・・・・・{Female-specific, e.g. pistil, ovule}

C12N 15/8234 ・・・・・・・・{Seed-specific, e.g. embryo, endosperm}

C12N 15/8235 ・・・・・・・・{Fruit-specific}

C12N 15/8237 ・・・・・・{Externally regulated expression systems}

C12N 15/8238 ・・・・・・・{chemically inducible, e.g. tetracycline}

C12N 15/8239 ・・・・・・・{pathogen inducible}

C12N 15/8241 ・・・・・{Phenotypically and genetically modified plants via recombinant DNA technology}

C12N 15/8242 ・・・・・・{with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits}

C12N 15/8243 ・・・・・・・{involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine}

C12N 15/8245 ・・・・・・・・{involving modified carbohydrate or sugar alcohol metabolism, e.g. starch biosynthesis}

C12N 15/8246 ・・・・・・・・・{Non-starch polysaccharides, e.g. cellulose, fructans, levans}

C12N 15/8247 ・・・・・・・・{involving modified lipid metabolism, e.g. seed oil composition}

C12N 15/8249 ・・・・・・・・{involving ethylene biosynthesis, senescence or fruit development, e.g. modified tomato ripening, cut flower shelf-life}

C12N 15/825 ・・・・・・・・{involving pigment biosynthesis}

C12N 15/8251 ・・・・・・・・{Amino acid content, e.g. synthetic storage proteins, altering amino acid biosynthesis}

C12N 15/8253 ・・・・・・・・・{Methionine or cysteine}

C12N 15/8254 ・・・・・・・・・{Tryptophan or lysine}

C12N 15/8255 ・・・・・・・・{involving lignin biosynthesis}

C12N 15/8257 ・・・・・・・{for the production of primary gene products, e.g. pharmaceutical products, interferon}

C12N 15/8258 ・・・・・・・・{for the production of oral vaccines (antigens) or immunoglobulins}

C12N 15/8259 ・・・・・・・{Phytoremediation}

C12N 15/8261 ・・・・・・{with agronomic (input) traits, e.g. crop yield}

C12N 15/8262 ・・・・・・・{involving plant development (not used)}

C12N 15/8263 ・・・・・・・・{Ablation; Apoptosis}

C12N 15/8265 ・・・・・・・・{Transgene containment, e.g. gene dispersal}

C12N 15/8266 ・・・・・・・・{Abscission; Dehiscence; Senescence}

C12N 15/8267 ・・・・・・・・{Seed dormancy, germination or sprouting}

C12N 15/8269 ・・・・・・・・{Photosynthesis}

C12N 15/827 ・・・・・・・・{Flower development or morphology, e.g. flowering promoting factor (FPF)}

C12N 15/8271 ・・・・・・・{for stress resistance, e.g. heavy metal resistance}

C12N 15/8273 ・・・・・・・・{for drought, cold, salt resistance}

C12N 15/8274 ・・・・・・・・{for herbicide resistance}

C12N 15/8275 ・・・・・・・・・{Glyphosate}

C12N 15/8277 ・・・・・・・・・{Phosphinotricin}

C12N 15/8278 ・・・・・・・・・{Sulfonylurea}

C12N 15/8279 ・・・・・・・・{for biotic stress resistance, pathogen resistance, disease resistance}

C12N 15/8281 ・・・・・・・・・{for bacterial resistance}

C12N 15/8282 ・・・・・・・・・{for fungal resistance}

C12N 15/8283 ・・・・・・・・・{for virus resistance}

C12N 15/8285 ・・・・・・・・・{for nematode resistance}

C12N 15/8286 ・・・・・・・・・{for insect resistance}

C12N 15/8287 ・・・・・・・{for fertility modification, e.g. apomixis}

C12N 15/8289 ・・・・・・・・{Male sterility}

C12N 15/829 ・・・・・・・・{Female sterility}

C12N 15/8291 ・・・・・・・{Hormone-influenced development}

C12N 15/8293 ・・・・・・・・{Abscisic acid (ABA)}

C12N 15/8294 ・・・・・・・・{Auxins}

C12N 15/8295 ・・・・・・・・{Cytokinins}

C12N 15/8297 ・・・・・・・・{Gibberellins; GA3}

C12N 15/8298 ・・・・・・・・{Brassinosteroids}

C12N 15/85 ・・・・for animal cells

C12N 15/8509 ・・・・・{for producing genetically modified animals, e.g. transgenic }

C12N 15/86 ・・・・・Viral vectors

C12N 15/861 ・・・・・・Adenoviral vectors

C12N 15/8613 ・・・・・・・{Chimaeric vector systems comprising heterologous sequences for production of another viral vector}

C12N 15/8616 ・・・・・・・{Special methods for targeting systems}

C12N 15/863 ・・・・・・Poxviral vectors, {e.g. entomopoxvirus}

C12N 15/8633 ・・・・・・・{Avian poxviral vectors}

C12N 15/8636 ・・・・・・・{Vaccina virus vectors}

C12N 15/864 ・・・・・・Parvoviral vectors, {e.g. parvovirus, densovirus}

C12N 15/8645 ・・・・・・・{Adeno-associated virus}

C12N 15/866 ・・・・・・Baculoviral vectors

C12N 15/867 ・・・・・・Retroviral vectors

C12N 15/8673 ・・・・・・・{Special methods for packaging systems}

C12N 15/8676 ・・・・・・・{Special methods for targeting systems}

C12N 15/869 ・・・・・・Herpesviral vectors

C12N 15/8695 ・・・・・・・{Herpes simplex virus-based vectors}

C12N 15/87 ・・Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

C12N 15/873 ・・・Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos

C12N 15/877 ・・・・Techniques for producing new mammalian cloned embroys

C12N 15/8771 ・・・・・{Bovine embryos}

C12N 15/8772 ・・・・・{Caprine embryos}

C12N 15/8773 ・・・・・{Ovine embryos}

C12N 15/8775 ・・・・・{Murine embryos}

C12N 15/8776 ・・・・・{Primate embryos}

C12N 15/8777 ・・・・・{Rabbit embryos}

C12N 15/8778 ・・・・・{Swine embryos}

C12N 15/88 ・・・using micro-encapsulation, e.g. using {amphiphile} liposome vesicle

C12N 15/89 ・・・using micro-injection

C12N 15/895 ・・・・{using biolistic methods}

C12N 15/90 ・・・Stable introduction of foreign DNA into chromosome

C12N 15/902 ・・・・{using homologous recombination}

C12N 15/905 ・・・・・{in geasts}

C12N 15/907 ・・・・・{in mammalian cells}

C12N 2009/00 Enzymes; Proenzymes; Compositions thereof (preparations containing enzymes for cleaning teeth A61K 8/66, A61Q 11/00; medicinal preparations containing enzymes or pro-enzymes A61K 38/43; enzyme containing detergent compositions C11D; {enzymes with nucleic acid structure, e.g. ribozymes, C12N 15/113}); Processes for preparing, activating, inhibiting, separating or purifying enzymes (preparation of malt C12C 1/00)

C12N 2009/02 ・Oxidoreductases (1.)

C12N 2015/00 Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (mutants or genetically engineered micro-organisms, per se C12N 1/00, C12N 5/00, C12N 7/00; new plants per se A01H; plant reproduction by tissue culture techniques A01H 4/00; new animals per se A01K 67/00; use of medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases, gene therapy A61K 48/00)

C12N 2015/09 ・Recombinant DNA-technology

C12N 2015/63 ・・Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

C12N 2015/79 ・・・Vectors or expression systems specially adapted for eukaryotic hosts

C12N 2015/85 ・・・・for animal cells

C12N 2015/8509 ・・・・・{for producing genetically modified animals, e.g. transgenic }

C12N 2015/8518 ・・・・・・{expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles}

C12N 2015/8527 ・・・・・・{for producing animal models, e.g. for tests or diseases}

C12N 2015/8536 ・・・・・・・{Animal models for genetic diseases}

C12N 2015/8545 ・・・・・・・・{for Alzheimer's disease}

C12N 2015/8554 ・・・・・・・・・{Invertebrates models for Alzheimer's disease}

C12N 2015/8563 ・・・・・・・・{for autoimmune diseases, e.g. Insulin-dependent diabetes mellitus}

C12N 2015/8572 ・・・・・・・{Animal models for proliferative diseases, e.g. comprising an oncogene}

C12N 2015/8581 ・・・・・・・{Animal models for infectious diseases, e.g. AIDS}

C12N 2015/859 ・・・・・・・{Animal models comprising reporter system for screening tests}

C12N 2303/00 Indexing codes associated with general methodologies in the field of biologically active non-coding nucleic acids

C12N 2310/00 Structure or type of the nucleic acid

C12N 2310/10 ・Type of nucleic acid

C12N 2310/11 ・・Antisense

C12N 2310/111 ・・・spanning the whole gene, or a large part of it

C12N 2310/113 ・・・targeting other non-coding nucleic acids, e.g. antagomirs

C12N 2310/12 ・・catalytic nucleic acids, e.g. ribozymes

C12N 2310/121 ・・・Hammerhead

C12N 2310/122 ・・・Hairpin

C12N 2310/123 ・・・Hepatitis delta

C12N 2310/124 ・・・based on group I or II introns

C12N 2310/1241 ・・・・Tetrahymena

C12N 2310/126 ・・・involving RNAse P

C12N 2310/127 ・・・DNAzymes

C12N 2310/128 ・・・processing or releasing ribozyme

C12N 2310/13 ・・Decoys

C12N 2310/14 ・・interfering N.A.

C12N 2310/141 ・・・MicroRNAs, miRNAs

C12N 2310/15 ・・Nucleic acids forming more than 2 strands, e.g. TFOs

C12N 2310/151 ・・・more than 3 strands, e.g. tetrads, H-DNA

C12N 2310/152 ・・・on a single-stranded target, e.g. fold-back TFOs

C12N 2310/153 ・・・with the aid of a protein, e.g. recombinase

C12N 2310/16 ・・Aptamers

C12N 2310/17 ・・Immunomodulatory nucleic acids

C12N 2310/18 ・・acting by a non-sequence specific mechanism (other than 310/16 or 310/17)

C12N 2310/30 ・Chemical structure

C12N 2310/31 ・・of the backbone

C12N 2310/311 ・・・Phosphotriesters

C12N 2310/312 ・・・Phosphonates

C12N 2310/3125 ・・・・Methylphosphonates

C12N 2310/313 ・・・Phosphorodithioates

C12N 2310/314 ・・・Phosphoramidates

C12N 2310/3145 ・・・・with the nitrogen in 3' or 5'-position

C12N 2310/315 ・・・Phosphorothioates

C12N 2310/316 ・・・Phosphonothioates

C12N 2310/317 ・・・with an inverted bond, e.g. a cap structure

C12N 2310/318 ・・・where the PO2 is completely replaced, e.g. MMI or formacetal

C12N 2310/3181 ・・・・Peptide nucleic acid, PNA

C12N 2310/3183 ・・・・Diol linkers, e.g. glycols or propanediols

C12N 2310/319 ・・・linked by 2'-5' linkages, i.e. having a free 3'-position

C12N 2310/32 ・・of the sugar

C12N 2310/321 ・・・2'-O-R Modification

C12N 2310/322 ・・・2'-R Modification

C12N 2310/323 ・・・modified ring structure

C12N 2310/3231 ・・・・having an additional ring, e.g. LNA, ENA

C12N 2310/3233 ・・・・Morpholino-type ring

C12N 2310/3235 ・・・・having the O of the ribose replaced by another atom

C12N 2310/33 ・・of the base

C12N 2310/331 ・・・Universal or degenerate base

C12N 2310/332 ・・・Abasic residue

C12N 2310/333 ・・・Modified A

C12N 2310/334 ・・・Modified C

C12N 2310/3341 ・・・・5-Methylcytosine

C12N 2310/335 ・・・Modified T or U

C12N 2310/336 ・・・Modified G

C12N 2310/337 ・・・in alpha-anomeric form

C12N 2310/34 ・・Spatial arrangement of the modifications

C12N 2310/341 ・・・Gapmers, i.e. of the type ===---===

C12N 2310/342 ・・・Hemimers, i.e. of the type ====----

C12N 2310/343 ・・・having patterns, e.g. ==--==--==--

C12N 2310/344 ・・・Position-specific modifications, e.g. on every purine, at the 3'-end

C12N 2310/345 ・・・having at least two different backbone modifications

C12N 2310/346 ・・・having a combination of backbone and sugar modifications

C12N 2310/35 ・・Nature of the modification

C12N 2310/351 ・・・Conjugate

C12N 2310/3511 ・・・・intercalating or cleaving agent

C12N 2310/3513 ・・・・Protein; Peptide

C12N 2310/3515 ・・・・Lipophilic moiety, e.g. cholesterol

C12N 2310/3517 ・・・・Marker; Tag

C12N 2310/3519 ・・・・Fusion with another nucleic acid

C12N 2310/352 ・・・linked to the nucleic acid via a carbon atom

C12N 2310/3521 ・・・・Methyl

C12N 2310/3523 ・・・・Allyl

C12N 2310/3525 ・・・・MOE, methoxyethoxy

C12N 2310/3527 ・・・・Other alkyl chain

C12N 2310/3529 ・・・・Aromatic substituent

C12N 2310/353 ・・・linked to the nucleic acid via an atom other than carbon

C12N 2310/3531 ・・・Hydrogen

C12N 2310/3533 ・・・Halogen

C12N 2310/3535 ・・・Nitrogen

C12N 2310/50 ・Physical structure

C12N 2310/51 ・・in polymeric form, e.g. multimers, concatemers

C12N 2310/52 ・・branched

C12N 2310/53 ・・partially self-complementary or closed

C12N 2310/531 ・・・Stem-loop; Hairpin

C12N 2310/532 ・・・Closed or circular

C12N 2310/533 ・・・having a mismatch or nick in at least one of the strands

C12N 2320/00 Applications; Uses

C12N 2320/10 ・in screening processes

C12N 2320/11 ・・for the determination of target sites, i.e. of active nucleic acids

C12N 2320/12 ・・in functional genomics, i.e. for the determination of gene function

C12N 2320/13 ・・in a process of directed evolution, e.g. SELEX, acquiring a new function

C12N 2320/30 ・Special therapeutic applications

C12N 2320/31 ・・Combination therapy

C12N 2320/32 ・・Special delivery means, e.g. tissue-specific

C12N 2320/33 ・・Alteration of splicing

C12N 2320/34 ・・Allele or polymorphism specific uses

C12N 2320/35 ・・based on a specific dosage / administration regimen

C12N 2320/50 ・Methods for regulating/modulating their activity

C12N 2320/51 ・・modulating the chemical stability, e.g. nuclease-resistance

C12N 2320/52 ・・modulating the physical stability, e.g. GC-content

C12N 2320/53 ・・reducing unwanted side-effects

C12N 2330/00 Production

C12N 2330/10 ・naturally occurring

C12N 2330/30 ・chemically synthesised

C12N 2330/31 ・・Libraries, arrays

C12N 2330/50 ・Biochemical production, i.e. in a transformed host cell

C12N 2330/51 ・・Specially adapted vectors

C12N 2500/00 Specific components of cell culture medium

C12N 2500/02 ・Atmosphere, e.g. low oxygen conditions

C12N 2500/05 ・Inorganic components

C12N 2500/10 ・・Metals; Metal chelators (cobalamine C12N 2500/38)

C12N 2500/12 ・・・Light metals, i.e. alkali, alkaline earth, Be, Al, Mg

C12N 2500/14 ・・・・Calcium; Ca chelators; Calcitonin

C12N 2500/16 ・・・・Magnesium; Mg chelators

C12N 2500/20 ・・・Transition metals

C12N 2500/22 ・・・・Zinc; Zn chelators (insulin-zinc complexes C12N 2501/33)

C12N 2500/24 ・・・・Iron; Fe chelators; Transferrin

C12N 2500/25 ・・・・・Insulin-transferrin; Insulin-transferrin-selenium

C12N 2500/30 ・Organic components (metal chelators C12N 2500/10; calcitonin C12N 2500/14; transferrin C12N 2500/24)

C12N 2500/32 ・・Amino acids

C12N 2500/33 ・・・other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine

C12N 2500/34 ・・Sugars

C12N 2500/35 ・・Polyols, e.g. glycerin, inositol

C12N 2500/36 ・・Lipids

C12N 2500/38 ・・Vitamins

C12N 2500/40 ・・Nucleotides, nucleosides, bases (cyclic nucleotides C12N 2501/01, anti-neoplasic drugs C12N 2501/06)

C12N 2500/42 ・・Organic phosphate, e.g. beta glycerophosphate

C12N 2500/44 ・・Thiols, e.g. mercaptoethanol

C12N 2500/46 ・・Amines, e.g. putrescine

C12N 2500/50 ・Soluble polymers, e.g. polyethyleneglycol (PEG)

C12N 2500/60 ・Buffer, e.g. pH regulation, osmotic pressure

C12N 2500/62 ・・DMSO

C12N 2500/70 ・Undefined extracts (conditioned medium C12N 2502/00)

C12N 2500/72 ・・from bacteria

C12N 2500/74 ・・from fungi, e.g. yeasts

C12N 2500/76 ・・from plants

C12N 2500/78 ・・from protozoa

C12N 2500/80 ・・from animals

C12N 2500/82 ・・・from invertebrates

C12N 2500/84 ・・・from mammals

C12N 2500/90 ・Serum-free medium, which may still contain naturally-sourced components

C12N 2500/92 ・・Medium free of human- or animal-derived components

C12N 2500/95 ・・Protein-free medium and culture conditions

C12N 2500/98 ・Xeno-free medium and culture conditions

C12N 2500/99 ・Serum-free medium

C12N 2501/00 Active agents used in cell culture processes, e.g. differentation

C12N 2501/01 ・Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin

C12N 2501/02 ・Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes

C12N 2501/03 ・Compounds acting on the NO pathway, e.g. nitrososarginine

C12N 2501/04 ・Immunosuppressors, e.g. cyclosporin, tacrolimus

C12N 2501/05 ・Adjuvants

C12N 2501/051 ・・Lipid A (MPA, MPL)

C12N 2501/052 ・・Lipopolysaccharides (LPS)

C12N 2501/054 ・・Muramyle peptides

C12N 2501/056 ・・Immunostimulating oligonucleotides, e.g. CpG

C12N 2501/06 ・Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide

C12N 2501/065 ・Modulators of histone acetylation

C12N 2501/07 ・Heat shock proteins

C12N 2501/10 ・Growth factors

C12N 2501/105 ・・Insulin-like growth factors (IGF)

C12N 2501/11 ・・Epidermal growth factor (EGF)

C12N 2501/113 ・・Acidic fibroblast growth factor (aFGF, FGF-1)

C12N 2501/115 ・・Basic fibroblast growth factor (bFGF, FGF-2)

C12N 2501/117 ・・Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)

C12N 2501/119 ・・Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10

C12N 2501/12 ・・Hepatocyte growth factor (HGF)

C12N 2501/125 ・・Stem cell factor (SCF), c-kit ligand (KL)

C12N 2501/13 ・・Nerve growth factor (NGF); Brain-derived neurotrophic factor (BDNF); Cilliary neurotrophic factor (CNTF); Glial-derived neurotrophic factor (GDNF); Neurotrophins (NT); Neuregulins

C12N 2501/135 ・・Platelet-derived growth factor (PDGF)

C12N 2501/14 ・・Erythropoietin (EPO)

C12N 2501/145 ・・Thrombopoietin (TPO)

C12N 2501/148 ・・Transforming growth factor alpha (TGF-a)

C12N 2501/15 ・・Transforming growth factor beta (TGF-?)

C12N 2501/155 ・・Bone morphogenic proteins (BMP); Osteogenins; Osteogenic factor; Bone inducing factor

C12N 2501/16 ・・Activin; Inhibin; Mullerian inhibiting substance

C12N 2501/165 ・・Vascular endothelial growth factor (VEGF)

C12N 2501/17 ・・Angiopoietin

C12N 2501/175 ・・Cardiotrophin

C12N 2501/18 ・・Liver cell growth factor (LCGF, Gly-His-Lys)

C12N 2501/185 ・・Osteoprotegerin; Osteoclast differentiation factor (ODF, RANKL)

C12N 2501/19 ・・Growth and differentiation factors (GDF)

C12N 2501/195 ・・Heregulin, neu differentiation factor

C12N 2501/20 ・Cytokines; Chemokines

C12N 2501/21 ・・Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4

C12N 2501/22 ・・Colony stimulating factors (G-CSF, GM-CSF)

C12N 2501/23 ・・Interleukins (IL)

C12N 2501/2301 ・・・Interleukin-1 (IL-1)

C12N 2501/2302 ・・・Interleukin-2 (IL-2)

C12N 2501/2303 ・・・Interleukin-3 (IL-3)

C12N 2501/2304 ・・・Interleukin-4 (IL-4)

C12N 2501/2305 ・・・Interleukin-5 (IL-5)

C12N 2501/2306 ・・・Interleukin-6 (IL-6)

C12N 2501/2307 ・・・Interleukin-7 (IL-7)

C12N 2501/2308 ・・・Interleukin-8 (IL-8)

C12N 2501/2309 ・・・Interleukin-9 (IL-9)

C12N 2501/231 ・・・Interleukin-10 (IL-10)

C12N 2501/2311 ・・・Interleukin-11 (IL-11)

C12N 2501/2312 ・・・Interleukin-12 (IL-12)

C12N 2501/2313 ・・・Interleukin-13 (IL-13)

C12N 2501/2314 ・・・Interleukin-14 (IL-14)

C12N 2501/2315 ・・・Interleukin-15 (IL-15)

C12N 2501/2316 ・・・Interleukin-16 (IL-16)

C12N 2501/2317 ・・・Interleukin-17 (IL-17)

C12N 2501/2318 ・・・Interleukin-18 (IL-18)

C12N 2501/2319 ・・・Interleukin-19 (IL-19)

C12N 2501/232 ・・・Interleukin-20 (IL-20)

C12N 2501/2321 ・・・Interleukin-21 (IL-21)

C12N 2501/2322 ・・・Interleukin-22 (IL-22)

C12N 2501/2323 ・・・Interleukin-23 (IL-23)

C12N 2501/2324 ・・・Interleukin-24 (IL-24)

C12N 2501/2325 ・・・Interleukin-25 (IL-25)

C12N 2501/2326 ・・・Interleukin-26 (IL-26)

C12N 2501/2327 ・・・Interleukin-27 (IL-27)

C12N 2501/2328 ・・・Interleukin-28 (IL-28)

C12N 2501/2329 ・・・Interleukin-29 (IL-29)

C12N 2501/233 ・・・Interleukin-30 (IL-30)

C12N 2501/2331 ・・・Interleukin-31 (IL-31)

C12N 2501/2332 ・・・Interleukin-32 (IL-32)

C12N 2501/2333 ・・・Interleukin-33 (IL-33)

C12N 2501/2334 ・・・Interleukin-34 (IL-34)

C12N 2501/2335 ・・・Interleukin-35 (IL-35)

C12N 2501/235 ・・・Leukemia inhibitory factor (LIF)

C12N 2501/237 ・・Oncostatin M (OSM)

C12N 2501/24 ・・Interferons (IFN)

C12N 2501/25 ・・Tumour necrosing factors (TNF)

C12N 2501/26 ・・Flt-3 ligand (CD135L, flk-2 ligand)

C12N 2501/30 ・Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C12N 2501/85)

C12N 2501/305 ・・Growth hormone (GH), aka. somatotropin

C12N 2501/31 ・・Pituitary sex hormones, e.g. follicle-stimulating hormone (FSH), luteinising hormone (LH); Chorionic gonadotropins

C12N 2501/315 ・・Prolactin

C12N 2501/32 ・・Angiotensins (AT), angiotensinogen

C12N 2501/33 ・・Insulin (together with transferrin C12N 2500/25; Insulin-like growth factors C12N 2501/105)

C12N 2501/335 ・・Glucagon; Glucagon-like peptide (GLP); Exendin

C12N 2501/34 ・・Calcitonin; Calcitonin-gene related peptide (CGRO); Amylin

C12N 2501/345 ・・Gastrin; Cholecystokinins (CCK)

C12N 2501/35 ・・Vasoactive intestinal peptide (VIP); Pituitary adenylate cyclase activating polypeptide (PACAP)

C12N 2501/355 ・・Leptin

C12N 2501/36 ・・Somatostatin

C12N 2501/365 ・・Endothelin

C12N 2501/37 ・・Parathyroid hormone (PTH)

C12N 2501/375 ・・Thyroid stimulating hormone (TSH)

C12N 2501/38 ・・with nuclear receptors

C12N 2501/385 ・・・of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor (PPAR)

C12N 2501/39 ・・・Steroid hormones

C12N 2501/392 ・・・・Sexual steroids

C12N 2501/395 ・・・Thyroid hormones

C12N 2501/40 ・Regulators of development

C12N 2501/405 ・・Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases

C12N 2501/41 ・・Hedgehog proteins; Cyclopamine (inhibitor)

C12N 2501/415 ・・Wnt; Frizzeled

C12N 2501/42 ・・Notch; Delta; Jagged; Serrate

C12N 2501/48 ・・Regulators of apoptosis

C12N 2501/50 ・Cell markers; Cell surface determinants

C12N 2501/505 ・・CD4; CD8

C12N 2501/51 ・・B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)

C12N 2501/515 ・・CD3, T-cell receptor complex

C12N 2501/52 ・・CD40, CD40-ligand (CD154)

C12N 2501/53 ・・CD2

C12N 2501/58 ・・Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand)

C12N 2501/585 ・・Integrins

C12N 2501/59 ・・Lectins

C12N 2501/599 ・・with CD designations not provided for elsewhere

C12N 2501/60 ・Transcription factors

C12N 2501/602 ・・Sox-2

C12N 2501/603 ・・Oct-3/4

C12N 2501/604 ・・Klf-4

C12N 2501/605 ・・Nanog

C12N 2501/606 ・・c-Myc

C12N 2501/608 ・・Lin28

C12N 2501/65 ・Micro-RNA

C12N 2501/70 ・Enzymes

C12N 2501/71 ・・Oxidoreductases (EC 1.)

C12N 2501/72 ・・Transferases (EC 2.)(acetylation of histones C12N 2501/065)

C12N 2501/724 ・・・Glycosyltransferases (EC 2.4.)

C12N 2501/727 ・・・Kinases (EC 2.7.)

C12N 2501/73 ・・Hydrolases (EC 3.)

C12N 2501/734 ・・・Proteases (EC 3.4.)

C12N 2501/80 ・Neurotransmitters; Neurohormones

C12N 2501/805 ・・Acetylcholine

C12N 2501/81 ・・Adrenaline

C12N 2501/815 ・・Dopamine

C12N 2501/82 ・・Histamine

C12N 2501/825 ・・Serotonine (5-HT); Melatonine

C12N 2501/83 ・・Tachykinins, e.g. substance P

C12N 2501/835 ・・Neuropeptide Y (NPY); Peptide YY (PYY)

C12N 2501/84 ・・Excitatory amino acids

C12N 2501/845 ・・Gamma amino butyric acid (GABA)

C12N 2501/85 ・Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin

C12N 2501/855 ・・Corticotropin (ACTH)

C12N 2501/86 ・・Melanocyte-stimulating hormone (MSH)

C12N 2501/90 ・Polysaccharides

C12N 2501/905 ・・Hyaluronic acid

C12N 2501/91 ・・Heparin

C12N 2501/998 ・Proteins not provided for elsewhere

C12N 2501/999 ・Small molecules not provided for elsewhere

C12N 2502/00 Coculture with; Conditioned medium produced by

C12N 2502/02 ・embryonic cells

C12N 2502/025 ・・extra-embryonic cells, e.g. amniotic epithelium, placental cells, Wharton's jelly

C12N 2502/03 ・non-embryonic pluripotent stem cells

C12N 2502/04 ・germ cells

C12N 2502/07 ・endocrine cells

C12N 2502/072 ・・adrenal cells

C12N 2502/074 ・・pinealocytes

C12N 2502/076 ・・pituitary cells

C12N 2502/078 ・・thyroid, parathyroid cells

C12N 2502/08 ・cells of the nervous system

C12N 2502/081 ・・neurons

C12N 2502/083 ・・sensory transducers

C12N 2502/085 ・・eye cells

C12N 2502/086 ・・glial cells

C12N 2502/088 ・・neural stem cells

C12N 2502/09 ・epidermal cells, skin cells, oral mucosa cells

C12N 2502/091 ・・melanocytes

C12N 2502/092 ・・hair cells

C12N 2502/094 ・・keratinocytes

C12N 2502/095 ・・mammary cells

C12N 2502/097 ・・oral mucosa cells

C12N 2502/098 ・・cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrymal glands

C12N 2502/11 ・blood or immune system cells

C12N 2502/1107 ・・B cells

C12N 2502/1114 ・・T cells

C12N 2502/1121 ・・Dendritic cells

C12N 2502/1128 ・・Erythrocytes

C12N 2502/1135 ・・Granulocytes

C12N 2502/1142 ・・Osteoclasts

C12N 2502/115 ・・Platelets, megakaryocytes

C12N 2502/1157 ・・Monocytes, macrophages

C12N 2502/1164 ・・NK cells

C12N 2502/1171 ・・Haematopoietic stem cells

C12N 2502/1178 ・・Spleen cells

C12N 2502/1185 ・・Thymus cells

C12N 2502/1192 ・・Lymphatic cells

C12N 2502/13 ・connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"

C12N 2502/1305 ・・Adipocytes

C12N 2502/1311 ・・Osteocytes, osteoblasts, odontoblasts

C12N 2502/1317 ・・Chondrocytes

C12N 2502/1323 ・・Adult fibroblasts

C12N 2502/1329 ・・Cardiomyocytes

C12N 2502/1335 ・・Skeletal muscle cells, myocytes, myoblasts, myotubes

C12N 2502/1341 ・・Tenocytes, cells from tendons and ligaments

C12N 2502/1347 ・・Smooth muscle cells

C12N 2502/1352 ・・Mesenchymal stem cells

C12N 2502/1358 ・・・Bone marrow mesenchymal stem cells (BM-MSC)

C12N 2502/1364 ・・・Dental pulp stem cells, dental follicle stem cells

C12N 2502/137 ・・・Blood-borne mesenchymal stem cells, e.g. Msc from umbilical cord blood

C12N 2502/1376 ・・・Mesenchymal stem cells from hair follicles

C12N 2502/1382 ・・・Adipose-derived stem cells (ADSC), adipose stromal stem cells

C12N 2502/1388 ・・・Mesenchymal stem cells from other natural sources

C12N 2502/1394 ・・Bone marrow stromal cells; whole marrow

C12N 2502/14 ・hepatocytes

C12N 2502/16 ・fibroblasts

C12N 2502/21 ・bone marrow stromal cells

C12N 2502/22 ・pancreatic cells

C12N 2502/23 ・Gastro-intestinal tract cells

C12N 2502/24 ・Genital tract cells, non-germinal cells from gonads

C12N 2502/243 ・・Cells of the female genital tract , non-germinal ovarian cells

C12N 2502/246 ・・Cells of the male genital tract, non-germinal testis cells

C12N 2502/25 ・Urinary tract cells, renal cells

C12N 2502/253 ・・Bladder cells

C12N 2502/256 ・・Renal cells

C12N 2502/27 ・Lung cells, respiratory tract cells

C12N 2502/28 ・Vascular endothelial cells

C12N 2502/30 ・tumour cells

C12N 2502/45 ・Artificially induced pluripotent stem cells

C12N 2502/50 ・invertebrate cells

C12N 2502/70 ・Non-animal cells

C12N 2502/99 ・genetically modified cells

C12N 2503/00 Use of cells in diagnostics

C12N 2503/02 ・Drug screening

C12N 2503/04 ・Screening or testing on artificial tissues

C12N 2503/06 ・・Screening or testing on artificial skin

C12N 2506/00 Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells

C12N 2506/02 ・from embryonic cells

C12N 2506/025 ・・from extra-embryonic cells, e.g. trophoblast, placenta

C12N 2506/03 ・from non-embryonic pluripotent stem cells

C12N 2506/04 ・from germ cells

C12N 2506/07 ・from endocrine cells

C12N 2506/072 ・・from adrenal cells

C12N 2506/074 ・・from pinealocytes

C12N 2506/076 ・・from pituitary cells

C12N 2506/078 ・・from thyroid, parathyroid cells

C12N 2506/08 ・from cells of the nervous system

C12N 2506/09 ・from epidermal cells, from skin cells, from oral mucosa cells

C12N 2506/091 ・・from melanocytes

C12N 2506/092 ・・from hair cells

C12N 2506/094 ・・from keratinocytes

C12N 2506/095 ・・from mammary cells

C12N 2506/097 ・・from oral mucosa cells

C12N 2506/098 ・・from cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrymal glands

C12N 2506/11 ・from blood or immune system cells

C12N 2506/115 ・・from monocytes, from macrophages

C12N 2506/13 ・from connective tissue cells, from mesenchymal cells

C12N 2506/1307 ・・from adult fibroblasts

C12N 2506/1315 ・・from cardiomyocytes

C12N 2506/1323 ・・from skeletal muscle cells

C12N 2506/133 ・・from tenocytes

C12N 2506/1338 ・・from smooth muscle cells

C12N 2506/1346 ・・from mesenchymal stem cells

C12N 2506/1353 ・・・from bone marrow mesenchymal stem cells (BM-MSC)

C12N 2506/1361 ・・・from dental pulp or dental follicle stem cells

C12N 2506/1369 ・・・from blood-borne mesenchymal stem cells, e.g. MSC from umbilical blood

C12N 2506/1376 ・・・from mesenchymal stem cells derived from hair follicles

C12N 2506/1384 ・・・from adipose-derived stem cells (ADSC), from adipose stromal stem cells

C12N 2506/1392 ・・・from mesenchymal stem cells from other natural sources

C12N 2506/14 ・from hepatocytes

C12N 2506/21 ・from bone marrow stromal cells; from mesenchymal stem cells

C12N 2506/22 ・from pancreatic cells

C12N 2506/23 ・from cells of the gastro-intestinal tract

C12N 2506/24 ・from cells of the genital tract, from non-germinal gonad cells

C12N 2506/243 ・・from cells of the female genital tract cells, from non-germinal ovarian cells

C12N 2506/246 ・・from cells of the male genital tract cells, from non-germinal testis cells

C12N 2506/25 ・from renal cells, from cells of the urinary tract

C12N 2506/27 ・from lung cells, from cells of the respiratory tract

C12N 2506/28 ・from vascular endothelial cells

C12N 2506/30 ・from cancer cells, e.g. reversion of tumour cells

C12N 2506/45 ・from artificially induced pluripotent stem cells

C12N 2509/00 Methods for the dissociation of cells, e.g. specific use of enzymes

C12N 2509/10 ・Mechanical dissociation

C12N 2510/00 Genetically modified cells

C12N 2510/02 ・Cells for production

C12N 2510/04 ・Immortalised cells

C12N 2511/00 Cells for large scale production

C12N 2513/00 3D culture

C12N 2517/00 Cells related to new breeds of animals

C12N 2517/02 ・Cells from transgenic animals

C12N 2517/04 ・Cells produced using nuclear transfer

C12N 2517/10 ・Conditioning of cells for in vitro fecondation or nuclear transfer

C12N 2521/00 Culture process characterised by the use of hydrostatic pressure, flow or shear forces

C12N 2521/10 ・Sound, e.g. ultrasounds

C12N 2523/00 Culture process characterised by temperature

C12N 2525/00 Culture process characterised by gravity, e.g. microgravity

C12N 2527/00 Culture process characterised by the use of mechanical forces, e.g. strain, vibration

C12N 2529/00 Culture process characterised by the use of electromagnetic stimulation

C12N 2529/10 ・Stimulation by light

C12N 2531/00 Microcarriers

C12N 2533/00 Supports or coatings for cell culture, characterised by material

C12N 2533/10 ・Mineral substrates

C12N 2533/12 ・・Glass

C12N 2533/14 ・・Ceramic

C12N 2533/18 ・・Calcium salts, e.g. apatite, Mineral components from bones, teeth, shells

C12N 2533/20 ・Small organic molecules

C12N 2533/30 ・Synthetic polymers (thermoreactive polymers, e.g. PNIPAm, C12N 2539/10)

C12N 2533/32 ・・Polylysine, polyornithine

C12N 2533/40 ・・Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers

C12N 2533/50 ・Proteins

C12N 2533/52 ・・Fibronectin; Laminin

C12N 2533/54 ・・Collagen; Gelatin

C12N 2533/56 ・・Fibrin; Thrombin

C12N 2533/70 ・Polysaccharides

C12N 2533/72 ・・Chitin, chitosan

C12N 2533/74 ・・Alginate

C12N 2533/76 ・・Agarose, agar-agar

C12N 2533/78 ・・Cellulose

C12N 2533/80 ・・Hyaluronan

C12N 2533/90 ・Substrates of biological origin, e.g. extracellular matrix, decellularised tissue

C12N 2533/92 ・・Amnion; Decellularised dermis or mucosa

C12N 2535/00 Supports or coatings for cell culture characterised by topography

C12N 2535/10 ・Patterned coating

C12N 2537/00 Supports and/or coatings for cell culture characterised by physical or chemical treatment

C12N 2537/10 ・Cross-linking

C12N 2539/00 Supports and/or coatings for cell culture characterised by properties

C12N 2539/10 ・Coating allowing for selective detachment of cells, e.g. thermoreactive coating

C12N 2700/00 Viruses

C12N 2710/00 DsDNA Viruses (not used)

C12N 2710/00011 ・dsDNA Viruses

C12N 2710/00021 ・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2710/00022 ・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2710/00023 ・・Virus like particles [VLP]

C12N 2710/00031 ・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2710/00032 ・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2710/00033 ・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2710/00034 ・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2710/00041 ・・Use of virus, viral particle or viral elements as a vector

C12N 2710/00042 ・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2710/00043 ・・・viral genome or elements thereof as genetic vector

C12N 2710/00044 ・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2710/00045 ・・・Special targeting system for viral vectors

C12N 2710/00051 ・・Methods of production or purification of viral material

C12N 2710/00052 ・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2710/00061 ・・Methods of inactivation or attenuation

C12N 2710/00062 ・・・by genetic engineering

C12N 2710/00063 ・・・by chemical treatment

C12N 2710/00064 ・・・by serial passage

C12N 2710/00071 ・・Demonstrated in vivo effect

C12N 2710/00088 ・・For redistribution

C12N 2710/10011 ・・Adenoviridae

C12N 2710/10021 ・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2710/10022 ・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2710/10023 ・・・Virus like particles [VLP]

C12N 2710/10031 ・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2710/10032 ・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2710/10033 ・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2710/10034 ・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2710/10041 ・・・Use of virus, viral particle or viral elements as a vector

C12N 2710/10042 ・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2710/10043 ・・・・viral genome or elements thereof as genetic vector

C12N 2710/10044 ・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2710/10045 ・・・・Special targeting system for viral vectors

C12N 2710/10051 ・・・Methods of production or purification of viral material

C12N 2710/10052 ・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2710/10061 ・・・Methods of inactivation or attenuation

C12N 2710/10062 ・・・・by genetic engineering

C12N 2710/10063 ・・・・by chemical treatment

C12N 2710/10064 ・・・・by serial passage

C12N 2710/10071 ・・・Demonstrated in vivo effect

C12N 2710/10088 ・・・For redistribution

C12N 2710/10111 ・・・Atadenovirus, e.g. ovine adenovirus D

C12N 2710/10121 ・・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2710/10122 ・・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2710/10123 ・・・・Virus like particles [VLP]

C12N 2710/10131 ・・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2710/10132 ・・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2710/10133 ・・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2710/10134 ・・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2710/10141 ・・・・Use of virus, viral particle or viral elements as a vector

C12N 2710/10142 ・・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2710/10143 ・・・・・viral genome or elements thereof as genetic vector

C12N 2710/10144 ・・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2710/10145 ・・・・・Special targeting system for viral vectors

C12N 2710/10151 ・・・・Methods of production or purification of viral material

C12N 2710/10152 ・・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2710/10161 ・・・・Methods of inactivation or attenuation

C12N 2710/10162 ・・・・・by genetic engineering

C12N 2710/10163 ・・・・・by chemical treatment

C12N 2710/10164 ・・・・・by serial passage

C12N 2710/10171 ・・・・Demonstrated in vivo effect

C12N 2710/10188 ・・・・For redistribution

C12N 2710/10211 ・・・Aviadenovirus, e.g. fowl adenovirus A

C12N 2710/10221 ・・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2710/10222 ・・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2710/10223 ・・・・Virus like particles [VLP]

C12N 2710/10231 ・・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2710/10232 ・・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2710/10233 ・・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2710/10234 ・・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2710/10241 ・・・・Use of virus, viral particle or viral elements as a vector

C12N 2710/10242 ・・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2710/10243 ・・・・・viral genome or elements thereof as genetic vector

C12N 2710/10244 ・・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2710/10245 ・・・・・Special targeting system for viral vectors

C12N 2710/10251 ・・・・Methods of production or purification of viral material

C12N 2710/10252 ・・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2710/10261 ・・・・Methods of inactivation or attenuation

C12N 2710/10262 ・・・・・by genetic engineering

C12N 2710/10263 ・・・・・by chemical treatment

C12N 2710/10264 ・・・・・by serial passage

C12N 2710/10271 ・・・・Demonstrated in vivo effect

C12N 2710/10288 ・・・・For redistribution

C12N 2710/10311 ・・・Mastadenovirus, e.g. human or simian adenoviruses

C12N 2710/10321 ・・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2710/10322 ・・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2710/10323 ・・・・Virus like particles [VLP]

C12N 2710/10331 ・・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2710/10332 ・・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2710/10333 ・・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2710/10334 ・・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2710/10341 ・・・・Use of virus, viral particle or viral elements as a vector

C12N 2710/10342 ・・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2710/10343 ・・・・・viral genome or elements thereof as genetic vector

C12N 2710/10344 ・・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2710/10345 ・・・・・Special targeting system for viral vectors

C12N 2710/10351 ・・・・Methods of production or purification of viral material

C12N 2710/10352 ・・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2710/10361 ・・・・Methods of inactivation or attenuation

C12N 2710/10362 ・・・・・by genetic engineering

C12N 2710/10363 ・・・・・by chemical treatment

C12N 2710/10364 ・・・・・by serial passage

C12N 2710/10371 ・・・・Demonstrated in vivo effect

C12N 2710/10388 ・・・・For redistribution

C12N 2710/12011 ・・Asfarviridae

C12N 2710/12021 ・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2710/12022 ・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2710/12023 ・・・Virus like particles [VLP]

C12N 2710/12031 ・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2710/12032 ・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2710/12033 ・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2710/12034 ・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2710/12041 ・・・Use of virus, viral particle or viral elements as a vector

C12N 2710/12042 ・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2710/12043 ・・・・viral genome or elements thereof as genetic vector

C12N 2710/12044 ・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2710/12045 ・・・・Special targeting system for viral vectors

C12N 2710/12051 ・・・Methods of production or purification of viral material

C12N 2710/12052 ・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2710/12061 ・・・Methods of inactivation or attenuation

C12N 2710/12062 ・・・・by genetic engineering

C12N 2710/12063 ・・・・by chemical treatment

C12N 2710/12064 ・・・・by serial passage

C12N 2710/12071 ・・・Demonstrated in vivo effect

C12N 2710/12088 ・・・For redistribution

C12N 2710/14011 ・・Baculoviridae

C12N 2710/14021 ・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2710/14022 ・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2710/14023 ・・・Virus like particles [VLP]

C12N 2710/14031 ・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2710/14032 ・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2710/14033 ・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2710/14034 ・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2710/14041 ・・・Use of virus, viral particle or viral elements as a vector

C12N 2710/14042 ・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2710/14043 ・・・・viral genome or elements thereof as genetic vectore

C12N 2710/14044 ・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2710/14045 ・・・・Special targeting system for viral vectors

C12N 2710/14051 ・・・Methods of production or purification of viral material

C12N 2710/14052 ・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2710/14061 ・・・Methods of inactivation or attenuation

C12N 2710/14062 ・・・・by genetic engineering

C12N 2710/14063 ・・・・by chemical treatment

C12N 2710/14064 ・・・・by serial passage

C12N 2710/14071 ・・・Demonstrated in vivo effect

C12N 2710/14088 ・・・For redistribution

C12N 2710/14111 ・・・Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus

C12N 2710/14121 ・・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2710/14122 ・・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2710/14123 ・・・・Virus like particles [VLP]

C12N 2710/14131 ・・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2710/14132 ・・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2710/14133 ・・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2710/14134 ・・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2710/14141 ・・・・Use of virus, viral particle or viral elements as a vector

C12N 2710/14142 ・・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2710/14143 ・・・・・viral genome or elements thereof as genetic vector

C12N 2710/14144 ・・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2710/14145 ・・・・・Special targeting system for viral vectors

C12N 2710/14151 ・・・・Methods of production or purification of viral material

C12N 2710/14152 ・・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2710/14161 ・・・・Methods of inactivation or attenuation

C12N 2710/14162 ・・・・・by genetic engineering

C12N 2710/14163 ・・・・・by chemical treatment

C12N 2710/14164 ・・・・・by serial passage

C12N 2710/14171 ・・・・Demonstrated in vivo effect

C12N 2710/14188 ・・・・For redistribution

C12N 2710/16011 ・・Herpesviridae

C12N 2710/16021 ・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2710/16022 ・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2710/16023 ・・・Virus like particles [VLP]

C12N 2710/16031 ・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2710/16032 ・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2710/16033 ・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2710/16034 ・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2710/16041 ・・・Use of virus, viral particle or viral elements as a vector

C12N 2710/16042 ・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2710/16043 ・・・・viral genome or elements thereof as genetic vector

C12N 2710/16044 ・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2710/16045 ・・・・Special targeting system for viral vectors

C12N 2710/16051 ・・・Methods of production or purification of viral material

C12N 2710/16052 ・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2710/16061 ・・・Methods of inactivation or attenuation

C12N 2710/16062 ・・・・by genetic engineering

C12N 2710/16063 ・・・・by chemical treatment

C12N 2710/16064 ・・・・by serial passage

C12N 2710/16071 ・・・Demonstrated in vivo effect

C12N 2710/16088 ・・・For redistribution

C12N 2710/16111 ・・・Cytomegalovirus, e.g. human herpesvirus 5

C12N 2710/16121 ・・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2710/16122 ・・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2710/16123 ・・・・Virus like particles [VLP]

C12N 2710/16131 ・・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2710/16132 ・・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2710/16133 ・・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2710/16134 ・・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2710/16141 ・・・・Use of virus, viral particle or viral elements as a vector

C12N 2710/16142 ・・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2710/16143 ・・・・・viral genome or elements thereof as genetic vector

C12N 2710/16144 ・・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2710/16145 ・・・・・Special targeting system for viral vectors

C12N 2710/16151 ・・・・Methods of production or purification of viral material

C12N 2710/16152 ・・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2710/16161 ・・・・Methods of inactivation or attenuation

C12N 2710/16162 ・・・・・by genetic engineering

C12N 2710/16163 ・・・・・by chemical treatment

C12N 2710/16164 ・・・・・by serial passage

C12N 2710/16171 ・・・・Demonstrated in vivo effect

C12N 2710/16188 ・・・・For redistribution

C12N 2710/16211 ・・・Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus

C12N 2710/16221 ・・・・Viruses as such, e.g. new isolates, mutants or their genomic sequencess

C12N 2710/16222 ・・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2710/16223 ・・・・Virus like particles [VLP]

C12N 2710/16231 ・・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2710/16232 ・・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2710/16233 ・・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2710/16234 ・・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2710/16241 ・・・・Use of virus, viral particle or viral elements as a vector

C12N 2710/16242 ・・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2710/16243 ・・・・・viral genome or elements thereof as genetic vector

C12N 2710/16244 ・・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2710/16245 ・・・・・Special targeting system for viral vectors

C12N 2710/16251 ・・・・Methods of production or purification of viral material

C12N 2710/16252 ・・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2710/16261 ・・・・Methods of inactivation or attenuation

C12N 2710/16262 ・・・・・by genetic engineering

C12N 2710/16263 ・・・・・by chemical treatment

C12N 2710/16264 ・・・・・by serial passage

C12N 2710/16271 ・・・・Demonstrated in vivo effect

C12N 2710/16288 ・・・・For redistribution

C12N 2710/16311 ・・・Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV

C12N 2710/16321 ・・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2710/16322 ・・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2710/16323 ・・・・Virus like particles [VLP]

C12N 2710/16331 ・・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2710/16332 ・・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2710/16333 ・・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2710/16334 ・・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2710/16341 ・・・・Use of virus, viral particle or viral elements as a vector

C12N 2710/16342 ・・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2710/16343 ・・・・・viral genome or elements thereof as genetic vector

C12N 2710/16344 ・・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2710/16345 ・・・・・Special targeting system for viral vectors

C12N 2710/16351 ・・・・Methods of production or purification of viral material

C12N 2710/16352 ・・・・・relating to complementin g cells and packaging systems for producing virus or viral particles

C12N 2710/16361 ・・・・Methods of inactivation or attenuation

C12N 2710/16362 ・・・・・by genetic engineering

C12N 2710/16363 ・・・・・by chemical treatment

C12N 2710/16364 ・・・・・by serial passage

C12N 2710/16371 ・・・・Demonstrated in vivo effect

C12N 2710/16388 ・・・・For redistribution

C12N 2710/16411 ・・・Rhadinovirus, e.g. human herpesvirus 8

C12N 2710/16421 ・・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2710/16422 ・・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2710/16423 ・・・・Virus like particles [VLP]

C12N 2710/16431 ・・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2710/16432 ・・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2710/16433 ・・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2710/16434 ・・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2710/16441 ・・・・Use of virus, viral particle or viral elements as a vector

C12N 2710/16442 ・・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2710/16443 ・・・・・viral genome or elements thereof as genetic vector

C12N 2710/16444 ・・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2710/16445 ・・・・・Special targeting system for viral vectors

C12N 2710/16451 ・・・・Methods of production or purification of viral material

C12N 2710/16452 ・・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2710/16461 ・・・・Methods of inactivation or attenuation

C12N 2710/16462 ・・・・・by genetic engineering

C12N 2710/16463 ・・・・・by chemical treatment

C12N 2710/16464 ・・・・・by serial passage

C12N 2710/16471 ・・・・Demonstrated in vivo effect

C12N 2710/16488 ・・・・For redistribution

C12N 2710/16511 ・・・Roseolovirus, e.g. human herpesvirus 6, 7

C12N 2710/16521 ・・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2710/16522 ・・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2710/16523 ・・・・Virus like particles [VLP]

C12N 2710/16531 ・・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2710/16532 ・・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2710/16533 ・・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2710/16534 ・・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral

C12N 2710/16541 ・・・・Use of virus, viral particle or viral elements as a vector

C12N 2710/16542 ・・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2710/16543 ・・・・・viral genome or elements thereof as genetic vector

C12N 2710/16544 ・・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2710/16545 ・・・・・Special targeting system for viral vectors

C12N 2710/16551 ・・・・Methods of production or purification of viral material

C12N 2710/16552 ・・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2710/16561 ・・・・Methods of inactivation or attenuation

C12N 2710/16562 ・・・・・by genetic engineering

C12N 2710/16563 ・・・・・by chemical treatment

C12N 2710/16564 ・・・・・by serial passage

C12N 2710/16571 ・・・・Demonstrated in vivo effect

C12N 2710/16588 ・・・・For redistribution

C12N 2710/16611 ・・・Simplexvirus, e.g. human herpesvirus 1, 2

C12N 2710/16621 ・・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2710/16622 ・・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2710/16623 ・・・・Virus like particles [VLP]

C12N 2710/16631 ・・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2710/16632 ・・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2710/16633 ・・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2710/16634 ・・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2710/16641 ・・・・Use of virus, viral particle or viral elements as a vector

C12N 2710/16642 ・・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2710/16643 ・・・・・viral genome or elements thereof as genetic vector

C12N 2710/16644 ・・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2710/16645 ・・・・・Special targeting system for viral vectors

C12N 2710/16651 ・・・・Methods of production or purification of viral material

C12N 2710/16652 ・・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2710/16661 ・・・・Methods of inactivation or attenuation

C12N 2710/16662 ・・・・・by genetic engineering

C12N 2710/16663 ・・・・・by chemical treatment

C12N 2710/16664 ・・・・・by serial passage

C12N 2710/16671 ・・・・Demonstrated in vivo effect

C12N 2710/16688 ・・・・For redistribution

C12N 2710/16711 ・・・Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies

C12N 2710/16721 ・・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2710/16722 ・・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2710/16723 ・・・・Virus like particles [VLP]

C12N 2710/16731 ・・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2710/16732 ・・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2710/16733 ・・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2710/16734 ・・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2710/16741 ・・・・Use of virus, viral particle or viral elements as a vector

C12N 2710/16742 ・・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2710/16743 ・・・・・viral genome or elements thereof as genetic vector

C12N 2710/16744 ・・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2710/16745 ・・・・・Special targeting system for viral vectors

C12N 2710/16751 ・・・・Methods of production or purification of viral material

C12N 2710/16752 ・・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2710/16761 ・・・・Methods of inactivation or attenuation

C12N 2710/16762 ・・・・・by genetic engineering

C12N 2710/16763 ・・・・・by chemical treatment

C12N 2710/16764 ・・・・・by serial passage

C12N 2710/16771 ・・・・Demonstrated in vivo effect

C12N 2710/16788 ・・・・For redistribution

C12N 2710/18011 ・・Nimaviridae

C12N 2710/18021 ・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2710/18022 ・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2710/18023 ・・・Virus like particles [VLP]

C12N 2710/18031 ・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2710/18032 ・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2710/18033 ・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2710/18034 ・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2710/18041 ・・・Use of virus, viral particle or viral elements as a vector

C12N 2710/18042 ・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2710/18043 ・・・・viral genome or elements thereof as genetic vector

C12N 2710/18044 ・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2710/18045 ・・・・Special targeting system for viral vectors

C12N 2710/18051 ・・・Methods of production or purification of viral material

C12N 2710/18052 ・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2710/18061 ・・・Methods of inactivation or attenuation

C12N 2710/18062 ・・・・by genetic engineering

C12N 2710/18063 ・・・・by chemical treatment

C12N 2710/18064 ・・・・by serial passage

C12N 2710/18071 ・・・Demonstrated in vivo effect

C12N 2710/18088 ・・・For redistribution

C12N 2710/20011 ・・Papillomaviridae

C12N 2710/20021 ・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2710/20022 ・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2710/20023 ・・・Virus like particles [VLP]

C12N 2710/20031 ・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2710/20032 ・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2710/20033 ・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2710/20034 ・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2710/20041 ・・・Use of virus, viral particle or viral elements as a vector

C12N 2710/20042 ・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2710/20043 ・・・・viral genome or elements thereof as genetic vector

C12N 2710/20044 ・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2710/20045 ・・・・Special targeting system for viral vectors

C12N 2710/20051 ・・・Methods of production or purification of viral material

C12N 2710/20052 ・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2710/20061 ・・・Methods of inactivation or attenuation

C12N 2710/20062 ・・・・by genetic engineering

C12N 2710/20063 ・・・・by chemical treatment

C12N 2710/20064 ・・・・by serial passage

C12N 2710/20071 ・・・Demonstrated in vivo effect

C12N 2710/20088 ・・・For redistribution

C12N 2710/22011 ・・Polyomaviridae, e.g. polyoma, SV40, JC

C12N 2710/22021 ・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2710/22022 ・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2710/22023 ・・・Virus like particles [VLP]

C12N 2710/22031 ・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2710/22032 ・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2710/22033 ・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2710/22034 ・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2710/22041 ・・・Use of virus, viral particle or viral elements as a vector

C12N 2710/22042 ・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2710/22043 ・・・・viral genome or elements thereof as genetic vector

C12N 2710/22044 ・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2710/22045 ・・・・Special targeting system for viral vectors

C12N 2710/22051 ・・・Methods of production or purification of viral material

C12N 2710/22052 ・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2710/22061 ・・・Methods of inactivation or attenuation

C12N 2710/22062 ・・・・by genetic engineering

C12N 2710/22063 ・・・・by chemical treatment

C12N 2710/22064 ・・・・by serial passage

C12N 2710/22071 ・・・Demonstrated in vivo effect

C12N 2710/22088 ・・・For redistribution

C12N 2710/24011 ・・Poxviridae

C12N 2710/24021 ・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2710/24022 ・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2710/24023 ・・・Virus like particles [VLP]

C12N 2710/24031 ・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2710/24032 ・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2710/24033 ・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2710/24034 ・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2710/24041 ・・・Use of virus, viral particle or viral elements as a vector

C12N 2710/24042 ・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2710/24043 ・・・・viral genome or elements thereof as genetic vector

C12N 2710/24044 ・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2710/24045 ・・・・Special targeting system for viral vectors

C12N 2710/24051 ・・・Methods of production or purification of viral material

C12N 2710/24052 ・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2710/24061 ・・・Methods of inactivation or attenuation

C12N 2710/24062 ・・・・by genetic engineering

C12N 2710/24063 ・・・・by chemical treatment

C12N 2710/24064 ・・・・by serial passage

C12N 2710/24071 ・・・Demonstrated in vivo effect

C12N 2710/24088 ・・・For redistribution

C12N 2710/24111 ・・・Orthopoxvirus, e.g. vaccinia virus, variola

C12N 2710/24121 ・・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2710/24122 ・・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2710/24123 ・・・・Virus like particles [VLP]

C12N 2710/24131 ・・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2710/24132 ・・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2710/24133 ・・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2710/24134 ・・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2710/24141 ・・・・Use of virus, viral particle or viral elements as a vector

C12N 2710/24142 ・・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2710/24143 ・・・・・viral genome or elements thereof as genetic vector

C12N 2710/24144 ・・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2710/24145 ・・・・・Special targeting system for viral vectors

C12N 2710/24151 ・・・・Methods of production or purification of viral material

C12N 2710/24152 ・・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2710/24161 ・・・・Methods of inactivation or attenuation

C12N 2710/24162 ・・・・・by genetic engineering

C12N 2710/24163 ・・・・・by chemical treatment

C12N 2710/24164 ・・・・・by serial passage

C12N 2710/24171 ・・・・Demonstrated in vivo effect

C12N 2710/24188 ・・・・For redistribution

C12N 2710/24211 ・・・Parapoxvirus, e.g. Orf virus

C12N 2710/24221 ・・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2710/24222 ・・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2710/24223 ・・・・Virus like particles [VLP]

C12N 2710/24231 ・・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2710/24232 ・・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2710/24233 ・・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2710/24234 ・・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2710/24241 ・・・・Use of virus, viral particle or viral elements as a vector

C12N 2710/24242 ・・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2710/24243 ・・・・・viral genome or elements thereof as genetic vector

C12N 2710/24244 ・・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2710/24245 ・・・・・Special targeting system for viral vectors

C12N 2710/24251 ・・・・Methods of production or purification of viral material

C12N 2710/24252 ・・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2710/24261 ・・・・Methods of inactivation or attenuation

C12N 2710/24262 ・・・・・by genetic engineering

C12N 2710/24263 ・・・・・by chemical treatment

C12N 2710/24264 ・・・・・by serial passage

C12N 2710/24271 ・・・・Demonstrated in vivo effect

C12N 2710/24288 ・・・・For redistribution

C12N 2720/00 DsRNA Viruses (not used)

C12N 2720/00011 ・dsRNA Viruses

C12N 2720/00021 ・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2720/00022 ・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2720/00023 ・・Virus like particles [VLP]

C12N 2720/00031 ・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2720/00032 ・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2720/00033 ・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2720/00034 ・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2720/00041 ・・Use of virus, viral particle or viral elements as a vector

C12N 2720/00042 ・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2720/00043 ・・・viral genome or elements thereof as genetic vector

C12N 2720/00044 ・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2720/00045 ・・・Special targeting system for viral vectors

C12N 2720/00051 ・・Methods of production or purification of viral material

C12N 2720/00052 ・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2720/00061 ・・Methods of inactivation or attenuation

C12N 2720/00062 ・・・by genetic engineering

C12N 2720/00063 ・・・by chemical treatment

C12N 2720/00064 ・・・by serial passage

C12N 2720/00071 ・・Demonstrated in vivo effect

C12N 2720/00088 ・・For redistribution

C12N 2720/10011 ・・Birnaviridae

C12N 2720/10021 ・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2720/10022 ・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2720/10023 ・・・Virus like particles [VLP]

C12N 2720/10031 ・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2720/10032 ・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2720/10033 ・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2720/10034 ・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2720/10041 ・・・Use of virus, viral particle or viral elements as a vectorn

C12N 2720/10042 ・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2720/10043 ・・・・viral genome or elements thereof as genetic vector

C12N 2720/10044 ・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2720/10045 ・・・・Special targeting system for viral vectors

C12N 2720/10051 ・・・Methods of production or purification of viral material

C12N 2720/10052 ・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2720/10061 ・・・Methods of inactivation or attenuation

C12N 2720/10062 ・・・・by genetic engineering

C12N 2720/10063 ・・・・by chemical treatment

C12N 2720/10064 ・・・・by serial passage

C12N 2720/10071 ・・・Demonstrated in vivo effect

C12N 2720/10088 ・・・For redistribution

C12N 2720/12011 ・・Reoviridae

C12N 2720/12021 ・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2720/12022 ・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2720/12023 ・・・Virus like particles [VLP]

C12N 2720/12031 ・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2720/12032 ・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2720/12033 ・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2720/12034 ・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2720/12041 ・・・Use of virus, viral particle or viral elements as a vector

C12N 2720/12042 ・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2720/12043 ・・・・viral genome or elements thereof as genetic vector

C12N 2720/12044 ・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2720/12045 ・・・・Special targeting system for viral vectors

C12N 2720/12051 ・・・Methods of production or purification of viral material

C12N 2720/12052 ・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2720/12061 ・・・Methods of inactivation or attenuation

C12N 2720/12062 ・・・・by genetic engineering

C12N 2720/12063 ・・・・by chemical treatment

C12N 2720/12064 ・・・・by serial passage

C12N 2720/12071 ・・・Demonstrated in vivo effect

C12N 2720/12088 ・・・For redistribution

C12N 2720/12111 ・・・Orbivirus, e.g. bluetongue virus

C12N 2720/12121 ・・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2720/12122 ・・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2720/12123 ・・・・Virus like particles [VLP]

C12N 2720/12131 ・・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2720/12132 ・・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2720/12133 ・・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2720/12134 ・・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2720/12141 ・・・・Use of virus, viral particle or viral elements as a vectorn

C12N 2720/12142 ・・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2720/12143 ・・・・・viral genome or elements thereof as genetic vector

C12N 2720/12144 ・・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2720/12145 ・・・・・Special targeting system for viral vectors

C12N 2720/12151 ・・・・Methods of production or purification of viral material

C12N 2720/12152 ・・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2720/12161 ・・・・Methods of inactivation or attenuation

C12N 2720/12162 ・・・・・by genetic engineering

C12N 2720/12163 ・・・・・by chemical treatment

C12N 2720/12164 ・・・・・by serial passage

C12N 2720/12171 ・・・・Demonstrated in vivo effect

C12N 2720/12188 ・・・・For redistribution

C12N 2720/12211 ・・・Orthoreovirus, e.g. mammalian orthoreovirus

C12N 2720/12221 ・・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2720/12222 ・・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2720/12223 ・・・・Virus like particles [VLP]

C12N 2720/12231 ・・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2720/12232 ・・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2720/12233 ・・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2720/12234 ・・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2720/12241 ・・・・Use of virus, viral particle or viral elements as a vector

C12N 2720/12242 ・・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2720/12243 ・・・・・viral genome or elements thereof as genetic vector

C12N 2720/12244 ・・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2720/12245 ・・・・・Special targeting system for viral vectors

C12N 2720/12251 ・・・・Methods of production or purification of viral material

C12N 2720/12252 ・・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2720/12261 ・・・・Methods of inactivation or attenuation

C12N 2720/12262 ・・・・・by genetic engineering

C12N 2720/12263 ・・・・・by chemical treatment

C12N 2720/12264 ・・・・・by serial passage

C12N 2720/12271 ・・・・Demonstrated in vivo effect

C12N 2720/12288 ・・・・For redistribution

C12N 2720/12311 ・・・Rotavirus, e.g. rotavirus A

C12N 2720/12321 ・・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2720/12322 ・・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2720/12323 ・・・・Virus like particles [VLP]

C12N 2720/12331 ・・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2720/12332 ・・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2720/12333 ・・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2720/12334 ・・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2720/12341 ・・・・Use of virus, viral particle or viral elements as a vector

C12N 2720/12342 ・・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2720/12343 ・・・・・viral genome or elements thereof as genetic vector

C12N 2720/12344 ・・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2720/12345 ・・・・・Special targeting system for viral vectors

C12N 2720/12351 ・・・・Methods of production or purification of viral material

C12N 2720/12352 ・・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2720/12361 ・・・・Methods of inactivation or attenuation

C12N 2720/12362 ・・・・・by genetic engineering

C12N 2720/12363 ・・・・・by chemical treatment

C12N 2720/12364 ・・・・・by serial passage

C12N 2720/12371 ・・・・Demonstrated in vivo effect

C12N 2720/12388 ・・・・For redistribution

C12N 2730/00 Reverse Transcribing DNA Viruses (not used)

C12N 2730/00011 ・Reverse Transcribing DNA Viruses

C12N 2730/00021 ・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2730/00022 ・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2730/00023 ・・Virus like particles [VLP]

C12N 2730/00031 ・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2730/00032 ・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2730/00033 ・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2730/00034 ・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2730/00041 ・・Use of virus, viral particle or viral elements as a vector

C12N 2730/00042 ・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2730/00043 ・・・viral genome or elements thereof as genetic vector

C12N 2730/00044 ・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2730/00045 ・・・Special targeting system for viral vectors

C12N 2730/00051 ・・Methods of production or purification of viral material

C12N 2730/00052 ・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2730/00061 ・・Methods of inactivation or attenuation

C12N 2730/00062 ・・・by genetic engineering

C12N 2730/00063 ・・・by chemical treatment

C12N 2730/00064 ・・・by serial passage

C12N 2730/00071 ・・Demonstrated in vivo effect

C12N 2730/00088 ・・For redistribution

C12N 2730/10011 ・・Hepadnaviridae

C12N 2730/10021 ・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2730/10022 ・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2730/10023 ・・・Virus like particles [VLP]

C12N 2730/10031 ・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2730/10032 ・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2730/10033 ・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2730/10034 ・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2730/10041 ・・・Use of virus, viral particle or viral elements as a vector

C12N 2730/10042 ・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2730/10043 ・・・・viral genome or elements thereof as genetic vector

C12N 2730/10044 ・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2730/10045 ・・・・Special targeting system for viral vectors

C12N 2730/10051 ・・・Methods of production or purification of viral material

C12N 2730/10052 ・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2730/10061 ・・・Methods of inactivation or attenuation

C12N 2730/10062 ・・・・by genetic engineering

C12N 2730/10063 ・・・・by chemical treatment

C12N 2730/10064 ・・・・by serial passage

C12N 2730/10071 ・・・Demonstrated in vivo effect

C12N 2730/10088 ・・・For redistribution

C12N 2730/10111 ・・・Orthohepadnavirus, e.g. hepatitis B virus

C12N 2730/10121 ・・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2730/10122 ・・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2730/10123 ・・・・Virus like particles [VLP]

C12N 2730/10131 ・・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2730/10132 ・・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2730/10133 ・・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2730/10134 ・・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2730/10141 ・・・・Use of virus, viral particle or viral elements as a vector

C12N 2730/10142 ・・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2730/10143 ・・・・・viral genome or elements thereof as genetic vector

C12N 2730/10144 ・・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2730/10145 ・・・・・Special targeting system for viral vectors

C12N 2730/10151 ・・・・Methods of production or purification of viral material

C12N 2730/10152 ・・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2730/10161 ・・・・Methods of inactivation or attenuation

C12N 2730/10162 ・・・・・by genetic engineering

C12N 2730/10163 ・・・・・by chemical treatment

C12N 2730/10164 ・・・・・by serial passage

C12N 2730/10171 ・・・・Demonstrated in vivo effect

C12N 2730/10188 ・・・・For redistribution

C12N 2740/00 Reverse Transcribing RNA Viruses (not used)

C12N 2740/00011 ・Reverse Transcribing RNA Viruses

C12N 2740/00021 ・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2740/00022 ・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2740/00023 ・・Virus like particles [VLP]

C12N 2740/00031 ・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2740/00032 ・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2740/00033 ・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2740/00034 ・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2740/00041 ・・Use of virus, viral particle or viral elements as a vector

C12N 2740/00042 ・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2740/00043 ・・・viral genome or elements thereof as genetic vector

C12N 2740/00044 ・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2740/00045 ・・・Special targeting system for viral vectors

C12N 2740/00051 ・・Methods of production or purification of viral material

C12N 2740/00052 ・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2740/00061 ・・Methods of inactivation or attenuation

C12N 2740/00062 ・・・by genetic engineering

C12N 2740/00063 ・・・by chemical treatment

C12N 2740/00064 ・・・by serial passage

C12N 2740/00071 ・・Demonstrated in vivo effect

C12N 2740/00088 ・・For redistribution

C12N 2740/10011 ・・Retroviridae

C12N 2740/10021 ・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2740/10022 ・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2740/10023 ・・・Virus like particles [VLP]

C12N 2740/10031 ・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2740/10032 ・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2740/10033 ・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2740/10034 ・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2740/10041 ・・・Use of virus, viral particle or viral elements as a vector

C12N 2740/10042 ・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2740/10043 ・・・・viral genome or elements thereof as genetic vector

C12N 2740/10044 ・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2740/10045 ・・・・Special targeting system for viral vectors

C12N 2740/10051 ・・・Methods of production or purification of viral material

C12N 2740/10052 ・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2740/10061 ・・・Methods of inactivation or attenuation

C12N 2740/10062 ・・・・by genetic engineering

C12N 2740/10063 ・・・・by chemical treatment

C12N 2740/10064 ・・・・by serial passage

C12N 2740/10071 ・・・Demonstrated in vivo effect

C12N 2740/10088 ・・・For redistribution

C12N 2740/11011 ・・・Alpharetrovirus, e.g. avian leucosis virus

C12N 2740/11021 ・・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2740/11022 ・・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2740/11023 ・・・・Virus like particles [VLP]

C12N 2740/11031 ・・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2740/11032 ・・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2740/11033 ・・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2740/11034 ・・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2740/11041 ・・・・Use of virus, viral particle or viral elements as a vector

C12N 2740/11042 ・・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2740/11043 ・・・・・viral genome or elements thereof as genetic vector

C12N 2740/11044 ・・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2740/11045 ・・・・・Special targeting system for viral vectors

C12N 2740/11051 ・・・・Methods of production or purification of viral material

C12N 2740/11052 ・・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2740/11061 ・・・・Methods of inactivation or attenuation

C12N 2740/11062 ・・・・・by genetic engineering

C12N 2740/11063 ・・・・・by chemical treatment

C12N 2740/11064 ・・・・・by serial passage

C12N 2740/11071 ・・・・Demonstrated in vivo effect

C12N 2740/11088 ・・・・For redistribution

C12N 2740/12011 ・・・Betaretrovirus, e.g. mouse mammary tumour virus

C12N 2740/12021 ・・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2740/12022 ・・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2740/12023 ・・・・Virus like particles [VLP]

C12N 2740/12031 ・・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2740/12032 ・・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2740/12033 ・・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2740/12034 ・・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2740/12041 ・・・・Use of virus, viral particle or viral elements as a vector

C12N 2740/12042 ・・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2740/12043 ・・・・・viral genome or elements thereof as genetic vector

C12N 2740/12044 ・・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2740/12045 ・・・・・Special targeting system for viral vectors

C12N 2740/12051 ・・・・Methods of production or purification of viral material

C12N 2740/12052 ・・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2740/12061 ・・・・Methods of inactivation or attenuation

C12N 2740/12062 ・・・・・by genetic engineering

C12N 2740/12063 ・・・・・by chemical treatment

C12N 2740/12064 ・・・・・by serial passage

C12N 2740/12071 ・・・・Demonstrated in vivo effect

C12N 2740/12088 ・・・・For redistribution

C12N 2740/13011 ・・・Gammaretrovirus, e.g. murine leukeamia virus

C12N 2740/13021 ・・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2740/13022 ・・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2740/13023 ・・・・Virus like particles [VLP]

C12N 2740/13031 ・・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2740/13032 ・・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2740/13033 ・・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2740/13034 ・・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2740/13041 ・・・・Use of virus, viral particle or viral elements as a vector

C12N 2740/13042 ・・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2740/13043 ・・・・・viral genome or elements thereof as genetic vector

C12N 2740/13044 ・・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2740/13045 ・・・・・Special targeting system for viral vectors

C12N 2740/13051 ・・・・Methods of production or purification of viral material

C12N 2740/13052 ・・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2740/13061 ・・・・Methods of inactivation or attenuation

C12N 2740/13062 ・・・・・by genetic engineering

C12N 2740/13063 ・・・・・by chemical treatment

C12N 2740/13064 ・・・・・by serial passage

C12N 2740/13071 ・・・・Demonstrated in vivo effect

C12N 2740/13088 ・・・・For redistribution

C12N 2740/14011 ・・・Deltaretrovirus, e.g. bovine leukeamia virus

C12N 2740/14021 ・・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2740/14022 ・・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2740/14023 ・・・・Virus like particles [VLP]

C12N 2740/14031 ・・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2740/14032 ・・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2740/14033 ・・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2740/14034 ・・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2740/14041 ・・・・Use of virus, viral particle or viral elements as a vector

C12N 2740/14042 ・・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2740/14043 ・・・・・viral genome or elements thereof as genetic vector

C12N 2740/14044 ・・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2740/14045 ・・・・・Special targeting system for viral vectors

C12N 2740/14051 ・・・・Methods of production or purification of viral material

C12N 2740/14052 ・・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2740/14061 ・・・・Methods of inactivation or attenuation

C12N 2740/14062 ・・・・・by genetic engineering

C12N 2740/14063 ・・・・・by chemical treatment

C12N 2740/14064 ・・・・・by serial passage

C12N 2740/14071 ・・・・Demonstrated in vivo effect

C12N 2740/14088 ・・・・For redistribution

C12N 2740/15011 ・・・Lentivirus, not HIV, e.g. FIV, SIV

C12N 2740/15021 ・・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2740/15022 ・・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2740/15023 ・・・・Virus like particles [VLP]

C12N 2740/15031 ・・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2740/15032 ・・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2740/15033 ・・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2740/15034 ・・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2740/15041 ・・・・Use of virus, viral particle or viral elements as a vector

C12N 2740/15042 ・・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2740/15043 ・・・・・viral genome or elements thereof as genetic vector

C12N 2740/15044 ・・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2740/15045 ・・・・・Special targeting system for viral vectors

C12N 2740/15051 ・・・・Methods of production or purification of viral material

C12N 2740/15052 ・・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2740/15061 ・・・・Methods of inactivation or attenuation

C12N 2740/15062 ・・・・・by genetic engineering

C12N 2740/15063 ・・・・・by chemical treatment

C12N 2740/15064 ・・・・・by serial passage

C12N 2740/15071 ・・・・Demonstrated in vivo effect

C12N 2740/15088 ・・・・For redistribution

C12N 2740/16011 ・・・Human Immunodeficiency Virus, HIV

C12N 2740/16021 ・・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2740/16022 ・・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2740/16023 ・・・・Virus like particles [VLP]

C12N 2740/16031 ・・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2740/16032 ・・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2740/16033 ・・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2740/16034 ・・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2740/16041 ・・・・Use of virus, viral particle or viral elements as a vector

C12N 2740/16042 ・・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2740/16043 ・・・・・viral genome or elements thereof as genetic vector

C12N 2740/16044 ・・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2740/16045 ・・・・・Special targeting system for viral vectors

C12N 2740/16051 ・・・・Methods of production or purification of viral material

C12N 2740/16052 ・・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2740/16061 ・・・・Methods of inactivation or attenuation

C12N 2740/16062 ・・・・・by genetic engineering

C12N 2740/16063 ・・・・・by chemical treatment

C12N 2740/16064 ・・・・・by serial passage

C12N 2740/16071 ・・・・Demonstrated in vivo effect

C12N 2740/16088 ・・・・For redistribution

C12N 2740/16111 ・・・・concerning HIV env

C12N 2740/16122 ・・・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2740/16134 ・・・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2740/16171 ・・・・・Demonstrated in vivo effect

C12N 2740/16188 ・・・・・For redistribution

C12N 2740/16211 ・・・・concerning HIV gagpol

C12N 2740/16222 ・・・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2740/16234 ・・・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2740/16271 ・・・・・Demonstrated in vivo effect

C12N 2740/16288 ・・・・・For redistribution

C12N 2740/16311 ・・・・concerning HIV regulatory proteins

C12N 2740/16322 ・・・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2740/16334 ・・・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2740/16371 ・・・・・Demonstrated in vivo effect

C12N 2740/16388 ・・・・・For redistribution

C12N 2740/17011 ・・・Spumavirus, e.g. chimpanzee foamy virus

C12N 2740/17021 ・・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2740/17022 ・・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2740/17023 ・・・・Virus like particles [VLP]

C12N 2740/17031 ・・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2740/17032 ・・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2740/17033 ・・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2740/17034 ・・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2740/17041 ・・・・Use of virus, viral particle or viral elements as a vector

C12N 2740/17042 ・・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2740/17043 ・・・・・viral genome or elements thereof as genetic vector

C12N 2740/17044 ・・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2740/17045 ・・・・・Special targeting system for viral vectors

C12N 2740/17051 ・・・・Methods of production or purification of viral material

C12N 2740/17052 ・・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2740/17061 ・・・・Methods of inactivation or attenuation

C12N 2740/17062 ・・・・・by genetic engineering

C12N 2740/17063 ・・・・・by chemical treatment

C12N 2740/17064 ・・・・・by serial passage

C12N 2740/17071 ・・・・Demonstrated in vivo effect

C12N 2740/17088 ・・・・For redistribution

C12N 2750/00 SsDNA Viruses (not used)

C12N 2750/00011 ・ssDNA Viruses

C12N 2750/00021 ・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2750/00022 ・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2750/00023 ・・Virus like particles [VLP]

C12N 2750/00031 ・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2750/00032 ・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2750/00033 ・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2750/00034 ・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2750/00041 ・・Use of virus, viral particle or viral elements as a vector

C12N 2750/00042 ・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2750/00043 ・・・viral genome or elements thereof as genetic vector

C12N 2750/00044 ・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2750/00045 ・・・Special targeting system for viral vectors

C12N 2750/00051 ・・Methods of production or purification of viral material

C12N 2750/00052 ・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2750/00061 ・・Methods of inactivation or attenuation

C12N 2750/00062 ・・・by genetic engineering

C12N 2750/00063 ・・・by chemical treatment

C12N 2750/00064 ・・・by serial passage

C12N 2750/00071 ・・Demonstrated in vivo effect

C12N 2750/00088 ・・For redistribution

C12N 2750/10011 ・・Circoviridae

C12N 2750/10021 ・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2750/10022 ・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2750/10023 ・・・Virus like particles [VLP]

C12N 2750/10031 ・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2750/10032 ・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2750/10033 ・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2750/10034 ・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2750/10041 ・・・Use of virus, viral particle or viral elements as a vector

C12N 2750/10042 ・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2750/10043 ・・・・viral genome or elements thereof as genetic vector

C12N 2750/10044 ・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2750/10045 ・・・・Special targeting system for viral vectors

C12N 2750/10051 ・・・Methods of production or purification of viral material

C12N 2750/10052 ・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2750/10061 ・・・Methods of inactivation or attenuation

C12N 2750/10062 ・・・・by genetic engineering

C12N 2750/10063 ・・・・by chemical treatment

C12N 2750/10064 ・・・・by serial passage

C12N 2750/10071 ・・・Demonstrated in vivo effect

C12N 2750/10088 ・・・For redistribution

C12N 2750/12011 ・・Geminiviridae

C12N 2750/12021 ・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2750/12022 ・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2750/12023 ・・・Virus like particles [VLP]

C12N 2750/12031 ・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2750/12032 ・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2750/12033 ・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2750/12034 ・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2750/12041 ・・・Use of virus, viral particle or viral elements as a vector

C12N 2750/12042 ・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2750/12043 ・・・・viral genome or elements thereof as genetic vector

C12N 2750/12044 ・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2750/12045 ・・・・Special targeting system for viral vectors

C12N 2750/12051 ・・・Methods of production or purification of viral material

C12N 2750/12052 ・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2750/12061 ・・・Methods of inactivation or attenuation

C12N 2750/12062 ・・・・by genetic engineering

C12N 2750/12063 ・・・・by chemical treatment

C12N 2750/12064 ・・・・by serial passage

C12N 2750/12071 ・・・Demonstrated in vivo effect

C12N 2750/12088 ・・・For redistribution

C12N 2750/14011 ・・Parvoviridae

C12N 2750/14021 ・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2750/14022 ・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2750/14023 ・・・Virus like particles [VLP]

C12N 2750/14031 ・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2750/14032 ・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2750/14033 ・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2750/14034 ・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2750/14041 ・・・Use of virus, viral particle or viral elements as a vector

C12N 2750/14042 ・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2750/14043 ・・・・viral genome or elements thereof as genetic vector

C12N 2750/14044 ・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2750/14045 ・・・・Special targeting system for viral vectors

C12N 2750/14051 ・・・Methods of production or purification of viral material

C12N 2750/14052 ・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2750/14061 ・・・Methods of inactivation or attenuation

C12N 2750/14062 ・・・・by genetic engineering

C12N 2750/14063 ・・・・by chemical treatment

C12N 2750/14064 ・・・・by serial passage

C12N 2750/14071 ・・・Demonstrated in vivo effect

C12N 2750/14088 ・・・For redistribution

C12N 2750/14111 ・・・Dependovirus, e.g. adenoassociated viruses

C12N 2750/14121 ・・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2750/14122 ・・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2750/14123 ・・・・Virus like particles [VLP]

C12N 2750/14131 ・・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2750/14132 ・・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2750/14133 ・・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2750/14134 ・・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2750/14141 ・・・・Use of virus, viral particle or viral elements as a vector

C12N 2750/14142 ・・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2750/14143 ・・・・・viral genome or elements thereof as genetic vector

C12N 2750/14144 ・・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2750/14145 ・・・・・Special targeting system for viral vectors

C12N 2750/14151 ・・・・Methods of production or purification of viral material

C12N 2750/14152 ・・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2750/14161 ・・・・Methods of inactivation or attenuation

C12N 2750/14162 ・・・・・by genetic engineering

C12N 2750/14163 ・・・・・by chemical treatment

C12N 2750/14164 ・・・・・by serial passage

C12N 2750/14171 ・・・・Demonstrated in vivo effect

C12N 2750/14188 ・・・・For redistribution

C12N 2750/14211 ・・・Erythrovirus, e.g. B19 virus

C12N 2750/14221 ・・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2750/14222 ・・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2750/14223 ・・・・Virus like particles [VLP]

C12N 2750/14231 ・・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2750/14232 ・・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2750/14233 ・・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2750/14234 ・・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2750/14241 ・・・・Use of virus, viral particle or viral elements as a vector

C12N 2750/14242 ・・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2750/14243 ・・・・・viral genome or elements thereof as genetic vector

C12N 2750/14244 ・・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2750/14245 ・・・・・Special targeting system for viral vectors

C12N 2750/14251 ・・・・Methods of production or purification of viral material

C12N 2750/14252 ・・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2750/14261 ・・・・Methods of inactivation or attenuation

C12N 2750/14262 ・・・・・by genetic engineering

C12N 2750/14263 ・・・・・by chemical treatment

C12N 2750/14264 ・・・・・by serial passage

C12N 2750/14271 ・・・・Demonstrated in vivo effect

C12N 2750/14288 ・・・・For redistribution

C12N 2750/14311 ・・・Parvovirus, e.g. minute virus of mice

C12N 2750/14321 ・・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2750/14322 ・・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2750/14323 ・・・・Virus like particles [VLP]

C12N 2750/14331 ・・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2750/14332 ・・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2750/14333 ・・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2750/14334 ・・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2750/14341 ・・・・Use of virus, viral particle or viral elements as a vector

C12N 2750/14342 ・・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2750/14343 ・・・・・viral genome or elements thereof as genetic vector

C12N 2750/14344 ・・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2750/14345 ・・・・・Special targeting system for viral vectors

C12N 2750/14351 ・・・・Methods of production or purification of viral material

C12N 2750/14352 ・・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2750/14361 ・・・・Methods of inactivation or attenuation

C12N 2750/14362 ・・・・・by genetic engineering

C12N 2750/14363 ・・・・・by chemical treatment

C12N 2750/14364 ・・・・・by serial passage

C12N 2750/14371 ・・・・Demonstrated in vivo effect

C12N 2750/14388 ・・・・For redistribution

C12N 2760/00 SsRNA Viruses negative-sense (not used)

C12N 2760/00011 ・ssRNA Viruses negative-sense

C12N 2760/00021 ・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2760/00022 ・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2760/00023 ・・Virus like particles [VLP]

C12N 2760/00031 ・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2760/00032 ・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2760/00033 ・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2760/00034 ・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2760/00041 ・・Use of virus, viral particle or viral elements as a vector

C12N 2760/00042 ・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2760/00043 ・・・viral genome or elements thereof as genetic vector

C12N 2760/00044 ・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2760/00045 ・・・Special targeting system for viral vectors

C12N 2760/00051 ・・Methods of production or purification of viral material

C12N 2760/00052 ・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2760/00061 ・・Methods of inactivation or attenuation

C12N 2760/00062 ・・・by genetic engineering

C12N 2760/00063 ・・・by chemical treatment

C12N 2760/00064 ・・・by serial passage

C12N 2760/00071 ・・Demonstrated in vivo effect

C12N 2760/00088 ・・For redistribution

C12N 2760/10011 ・・Arenaviridae

C12N 2760/10021 ・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2760/10022 ・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2760/10023 ・・・Virus like particles [VLP]

C12N 2760/10031 ・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2760/10032 ・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2760/10033 ・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2760/10034 ・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2760/10041 ・・・Use of virus, viral particle or viral elements as a vector

C12N 2760/10042 ・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2760/10043 ・・・・viral genome or elements thereof as genetic vector

C12N 2760/10044 ・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2760/10045 ・・・・Special targeting system for viral vectors

C12N 2760/10051 ・・・Methods of production or purification of viral material

C12N 2760/10052 ・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2760/10061 ・・・Methods of inactivation or attenuation

C12N 2760/10062 ・・・・by genetic engineering

C12N 2760/10063 ・・・・by chemical treatment

C12N 2760/10064 ・・・・by serial passage

C12N 2760/10071 ・・・Demonstrated in vivo effect

C12N 2760/10088 ・・・For redistribution

C12N 2760/10111 ・・・Deltavirus, e.g. hepatitis delta virus

C12N 2760/10121 ・・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2760/10122 ・・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2760/10123 ・・・・Virus like particles [VLP]

C12N 2760/10131 ・・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2760/10132 ・・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2760/10133 ・・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2760/10134 ・・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2760/10141 ・・・・Use of virus, viral particle or viral elements as a vector

C12N 2760/10142 ・・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2760/10143 ・・・・・viral genome or elements thereof as genetic vector

C12N 2760/10144 ・・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2760/10145 ・・・・・Special targeting system for viral vectors

C12N 2760/10151 ・・・・Methods of production or purification of viral material

C12N 2760/10152 ・・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2760/10161 ・・・・Methods of inactivation or attenuation

C12N 2760/10162 ・・・・・by genetic engineering

C12N 2760/10163 ・・・・・by chemical treatment

C12N 2760/10164 ・・・・・by serial passage

C12N 2760/10171 ・・・・Demonstrated in vivo effect

C12N 2760/10188 ・・・・For redistribution

C12N 2760/12011 ・・Bunyaviridae

C12N 2760/12021 ・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2760/12022 ・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2760/12023 ・・・Virus like particles [VLP]

C12N 2760/12031 ・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2760/12032 ・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2760/12033 ・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2760/12034 ・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2760/12041 ・・・Use of virus, viral particle or viral elements as a vector

C12N 2760/12042 ・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2760/12043 ・・・・viral genome or elements thereof as genetic vector

C12N 2760/12044 ・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2760/12045 ・・・・Special targeting system for viral vectors

C12N 2760/12051 ・・・Methods of production or purification of viral material

C12N 2760/12052 ・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2760/12061 ・・・Methods of inactivation or attenuation

C12N 2760/12062 ・・・・by genetic engineering

C12N 2760/12063 ・・・・by chemical treatment

C12N 2760/12064 ・・・・by serial passage

C12N 2760/12071 ・・・Demonstrated in vivo effect

C12N 2760/12088 ・・・For redistribution

C12N 2760/12111 ・・・Hantavirus, e.g. Hantaan virus

C12N 2760/12121 ・・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2760/12122 ・・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2760/12123 ・・・・Virus like particles [VLP]

C12N 2760/12131 ・・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2760/12132 ・・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2760/12133 ・・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2760/12134 ・・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2760/12141 ・・・・Use of virus, viral particle or viral elements as a vector

C12N 2760/12142 ・・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2760/12143 ・・・・・viral genome or elements thereof as genetic vector

C12N 2760/12144 ・・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2760/12145 ・・・・・Special targeting system for viral vectors

C12N 2760/12151 ・・・・Methods of production or purification of viral material

C12N 2760/12152 ・・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2760/12161 ・・・・Methods of inactivation or attenuation

C12N 2760/12162 ・・・・・by genetic engineering

C12N 2760/12163 ・・・・・by chemical treatment

C12N 2760/12164 ・・・・・by serial passage

C12N 2760/12171 ・・・・Demonstrated in vivo effect

C12N 2760/12188 ・・・・For redistribution

C12N 2760/12211 ・・・Phlebovirus, e.g. Rift Valley fever virus

C12N 2760/12221 ・・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2760/12222 ・・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2760/12223 ・・・・Virus like particles [VLP]

C12N 2760/12231 ・・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2760/12232 ・・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2760/12233 ・・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2760/12234 ・・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2760/12241 ・・・・Use of virus, viral particle or viral elements as a vector

C12N 2760/12242 ・・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2760/12243 ・・・・・viral genome or elements thereof as genetic vector

C12N 2760/12244 ・・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2760/12245 ・・・・・Special targeting system for viral vectors

C12N 2760/12251 ・・・・Methods of production or purification of viral material

C12N 2760/12252 ・・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2760/12261 ・・・・Methods of inactivation or attenuation

C12N 2760/12262 ・・・・・by genetic engineering

C12N 2760/12263 ・・・・・by chemical treatment

C12N 2760/12264 ・・・・・by serial passage

C12N 2760/12271 ・・・・Demonstrated in vivo effect

C12N 2760/12288 ・・・・For redistribution

C12N 2760/14011 ・・Filoviridae

C12N 2760/14021 ・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2760/14022 ・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2760/14023 ・・・Virus like particles [VLP]

C12N 2760/14031 ・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2760/14032 ・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2760/14033 ・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2760/14034 ・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2760/14041 ・・・Use of virus, viral particle or viral elements as a vector

C12N 2760/14042 ・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2760/14043 ・・・・viral genome or elements thereof as genetic vector

C12N 2760/14044 ・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2760/14045 ・・・・Special targeting system for viral vectors

C12N 2760/14051 ・・・Methods of production or purification of viral material

C12N 2760/14052 ・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2760/14061 ・・・Methods of inactivation or attenuation

C12N 2760/14062 ・・・・by genetic engineering

C12N 2760/14063 ・・・・by chemical treatment

C12N 2760/14064 ・・・・by serial passage

C12N 2760/14071 ・・・Demonstrated in vivo effect

C12N 2760/14088 ・・・For redistribution

C12N 2760/14111 ・・・Ebolavirus, e.g. Zaire ebolavirus

C12N 2760/14121 ・・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2760/14122 ・・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2760/14123 ・・・・Virus like particles [VLP]

C12N 2760/14131 ・・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2760/14132 ・・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2760/14133 ・・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2760/14134 ・・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2760/14141 ・・・・Use of virus, viral particle or viral elements as a vector

C12N 2760/14142 ・・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2760/14143 ・・・・・viral genome or elements thereof as genetic vector

C12N 2760/14144 ・・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2760/14145 ・・・・・Special targeting system for viral vectors

C12N 2760/14151 ・・・・Methods of production or purification of viral material

C12N 2760/14152 ・・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2760/14161 ・・・・Methods of inactivation or attenuation

C12N 2760/14162 ・・・・・by genetic engineering

C12N 2760/14163 ・・・・・by chemical treatment

C12N 2760/14164 ・・・・・by serial passage

C12N 2760/14171 ・・・・Demonstrated in vivo effect

C12N 2760/14188 ・・・・For redistribution

C12N 2760/14211 ・・・Marburgvirus, e.g. lake Victoria marburgvirus

C12N 2760/14221 ・・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2760/14222 ・・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2760/14223 ・・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2760/14231 ・・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2760/14232 ・・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2760/14233 ・・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2760/14234 ・・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2760/14241 ・・・・Use of virus, viral particle or viral elements as a vector

C12N 2760/14242 ・・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2760/14243 ・・・・・viral genome or elements thereof as genetic vector

C12N 2760/14244 ・・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2760/14245 ・・・・・Special targeting system for viral vectors

C12N 2760/14251 ・・・・Methods of production or purification of viral material

C12N 2760/14252 ・・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2760/14261 ・・・・Methods of inactivation or attenuation

C12N 2760/14262 ・・・・・by genetic engineering

C12N 2760/14263 ・・・・・by chemical treatment

C12N 2760/14264 ・・・・・by serial passage

C12N 2760/14271 ・・・・Demonstrated in vivo effect

C12N 2760/14288 ・・・・For redistribution

C12N 2760/16011 ・・Orthomyxoviridae

C12N 2760/16021 ・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2760/16022 ・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2760/16023 ・・・Virus like particles [VLP]

C12N 2760/16031 ・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2760/16032 ・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2760/16033 ・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2760/16034 ・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2760/16041 ・・・Use of virus, viral particle or viral elements as a vector

C12N 2760/16042 ・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2760/16043 ・・・・viral genome or elements thereof as genetic vector

C12N 2760/16044 ・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2760/16045 ・・・・Special targeting system for viral vectors

C12N 2760/16051 ・・・Methods of production or purification of viral material

C12N 2760/16052 ・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2760/16061 ・・・Methods of inactivation or attenuation

C12N 2760/16062 ・・・・by genetic engineering

C12N 2760/16063 ・・・・by chemical treatment

C12N 2760/16064 ・・・・by serial passage

C12N 2760/16071 ・・・Demonstrated in vivo effect

C12N 2760/16088 ・・・For redistribution

C12N 2760/16111 ・・・Influenzavirus A, i.e. influenza A virus

C12N 2760/16121 ・・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2760/16122 ・・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2760/16123 ・・・・Virus like particles [VLP]

C12N 2760/16131 ・・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2760/16132 ・・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2760/16133 ・・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2760/16134 ・・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2760/16141 ・・・・Use of virus, viral particle or viral elements as a vector

C12N 2760/16142 ・・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2760/16143 ・・・・・viral genome or elements thereof as genetic vector

C12N 2760/16144 ・・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2760/16145 ・・・・・Special targeting system for viral vectors

C12N 2760/16151 ・・・・Methods of production or purification of viral material

C12N 2760/16152 ・・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2760/16161 ・・・・Methods of inactivation or attenuation

C12N 2760/16162 ・・・・・by genetic engineering

C12N 2760/16163 ・・・・・by chemical treatment

C12N 2760/16164 ・・・・・by serial passage

C12N 2760/16171 ・・・・Demonstrated in vivo effect

C12N 2760/16188 ・・・・For redistribution

C12N 2760/16211 ・・・Influenzavirus B, i.e. influenza B virus

C12N 2760/16221 ・・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2760/16222 ・・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2760/16223 ・・・・Virus like particles [VLP]

C12N 2760/16231 ・・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2760/16232 ・・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2760/16233 ・・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2760/16234 ・・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2760/16241 ・・・・Use of virus, viral particle or viral elements as a vector

C12N 2760/16242 ・・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2760/16243 ・・・・・viral genome or elements thereof as genetic vector

C12N 2760/16244 ・・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2760/16245 ・・・・・Special targeting system for viral vectors

C12N 2760/16251 ・・・・Methods of production or purification of viral material

C12N 2760/16252 ・・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2760/16261 ・・・・Methods of inactivation or attenuation

C12N 2760/16262 ・・・・・by genetic engineering

C12N 2760/16263 ・・・・・by chemical treatment

C12N 2760/16264 ・・・・・by serial passage

C12N 2760/16271 ・・・・Demonstrated in vivo effect

C12N 2760/16288 ・・・・For redistribution

C12N 2760/16311 ・・・Influenzavirus C, i.e. influenza C virus

C12N 2760/16321 ・・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2760/16322 ・・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2760/16323 ・・・・Virus like particles [VLP]

C12N 2760/16331 ・・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2760/16332 ・・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2760/16333 ・・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2760/16334 ・・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2760/16341 ・・・・Use of virus, viral particle or viral elements as a vector

C12N 2760/16342 ・・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2760/16343 ・・・・・viral genome or elements thereof as genetic vector

C12N 2760/16344 ・・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2760/16345 ・・・・・Special targeting system for viral vectors

C12N 2760/16351 ・・・・Methods of production or purification of viral material

C12N 2760/16352 ・・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2760/16361 ・・・・Methods of inactivation or attenuation

C12N 2760/16362 ・・・・・by genetic engineering

C12N 2760/16363 ・・・・・by chemical treatment

C12N 2760/16364 ・・・・・by serial passage

C12N 2760/16371 ・・・・Demonstrated in vivo effect

C12N 2760/16388 ・・・・For redistribution

C12N 2760/18011 ・・Paramyxoviridae

C12N 2760/18021 ・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2760/18022 ・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2760/18023 ・・・Virus like particles [VLP]

C12N 2760/18031 ・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2760/18032 ・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2760/18033 ・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2760/18034 ・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2760/18041 ・・・Use of virus, viral particle or viral elements as a vector

C12N 2760/18042 ・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2760/18043 ・・・・viral genome or elements thereof as genetic vector

C12N 2760/18044 ・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2760/18045 ・・・・Special targeting system for viral vectors

C12N 2760/18051 ・・・Methods of production or purification of viral material

C12N 2760/18052 ・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2760/18061 ・・・Methods of inactivation or attenuation

C12N 2760/18062 ・・・・by genetic engineering

C12N 2760/18063 ・・・・by chemical treatment

C12N 2760/18064 ・・・・by serial passage

C12N 2760/18071 ・・・Demonstrated in vivo effect

C12N 2760/18088 ・・・For redistribution

C12N 2760/18111 ・・・Avulavirus, e.g. Newcastle disease virus

C12N 2760/18121 ・・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2760/18122 ・・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2760/18123 ・・・・Virus like particles [VLP]

C12N 2760/18131 ・・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2760/18132 ・・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2760/18133 ・・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2760/18134 ・・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2760/18141 ・・・・Use of virus, viral particle or viral elements as a vector

C12N 2760/18142 ・・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2760/18143 ・・・・・viral genome or elements thereof as genetic vector

C12N 2760/18144 ・・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2760/18145 ・・・・・Special targeting system for viral vectors

C12N 2760/18151 ・・・・Methods of production or purification of viral material

C12N 2760/18152 ・・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2760/18161 ・・・・Methods of inactivation or attenuation

C12N 2760/18162 ・・・・・by genetic engineering

C12N 2760/18163 ・・・・・by chemical treatment

C12N 2760/18164 ・・・・・by serial passage

C12N 2760/18171 ・・・・Demonstrated in vivo effect

C12N 2760/18188 ・・・・For redistribution

C12N 2760/18211 ・・・Henipavirus, e.g. hendra virus

C12N 2760/18221 ・・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2760/18222 ・・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2760/18223 ・・・・Virus like particles [VLP]

C12N 2760/18231 ・・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2760/18232 ・・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2760/18233 ・・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2760/18234 ・・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2760/18241 ・・・・Use of virus, viral particle or viral elements as a vector

C12N 2760/18242 ・・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2760/18243 ・・・・・viral genome or elements thereof as genetic vector

C12N 2760/18244 ・・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2760/18245 ・・・・・Special targeting system for viral vectors

C12N 2760/18251 ・・・・Methods of production or purification of viral material

C12N 2760/18252 ・・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2760/18261 ・・・・Methods of inactivation or attenuation

C12N 2760/18262 ・・・・・by genetic engineering

C12N 2760/18263 ・・・・・by chemical treatment

C12N 2760/18264 ・・・・・by serial passage

C12N 2760/18271 ・・・・Demonstrated in vivo effect

C12N 2760/18288 ・・・・For redistribution

C12N 2760/18311 ・・・Metapneumovirus, e.g. avian pneumovirus

C12N 2760/18321 ・・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2760/18322 ・・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2760/18323 ・・・・Virus like particles [VLP]

C12N 2760/18331 ・・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2760/18332 ・・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2760/18333 ・・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2760/18334 ・・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2760/18341 ・・・・Use of virus, viral particle or viral elements as a vector

C12N 2760/18342 ・・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2760/18343 ・・・・・viral genome or elements thereof as genetic vector

C12N 2760/18344 ・・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2760/18345 ・・・・・Special targeting system for viral vectors

C12N 2760/18351 ・・・・Methods of production or purification of viral material

C12N 2760/18352 ・・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2760/18361 ・・・・Methods of inactivation or attenuation

C12N 2760/18362 ・・・・・by genetic engineering

C12N 2760/18363 ・・・・・by chemical treatment

C12N 2760/18364 ・・・・・by serial passage

C12N 2760/18371 ・・・・Demonstrated in vivo effect

C12N 2760/18388 ・・・・For redistribution

C12N 2760/18411 ・・・Morbillivirus, e.g. Measles virus, canine distemper

C12N 2760/18421 ・・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2760/18422 ・・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2760/18423 ・・・・Virus like particles [VLP]

C12N 2760/18431 ・・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2760/18432 ・・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2760/18433 ・・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2760/18434 ・・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2760/18441 ・・・・Use of virus, viral particle or viral elements as a vector

C12N 2760/18442 ・・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2760/18443 ・・・・・viral genome or elements thereof as genetic vector

C12N 2760/18444 ・・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2760/18445 ・・・・・Special targeting system for viral vectors

C12N 2760/18451 ・・・・Methods of production or purification of viral material

C12N 2760/18452 ・・・・・relating to complementing cells and packaging systems for producing virus or viral particles

C12N 2760/18461 ・・・・Methods of inactivation or attenuation

C12N 2760/18462 ・・・・・by genetic engineering

C12N 2760/18463 ・・・・・by chemical treatment

C12N 2760/18464 ・・・・・by serial passage

C12N 2760/18471 ・・・・Demonstrated in vivo effect

C12N 2760/18488 ・・・・For redistribution

C12N 2760/18511 ・・・Pneumovirus, e.g. human respiratory syncytial virus

C12N 2760/18521 ・・・・Viruses as such, e.g. new isolates, mutants or their genomic sequences

C12N 2760/18522 ・・・・New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

C12N 2760/18523 ・・・・Virus like particles [VLP]

C12N 2760/18531 ・・・・Uses of virus other than therapeutic or vaccine, e.g. disinfectant

C12N 2760/18532 ・・・・Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

C12N 2760/18533 ・・・・Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

C12N 2760/18534 ・・・・Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

C12N 2760/18541 ・・・・Use of virus, viral particle or viral elements as a vector

C12N 2760/18542 ・・・・・virus or viral particle as vehicle, e.g. encapsulating small organic molecule

C12N 2760/18543 ・・・・・viral genome or elements thereof as genetic vector

C12N 2760/18544 ・・・・・Chimeric viral vector comprising heterologous viral elements for production of another viral vector

C12N 2760/18545 ・・・・・Special targeting system for viral vectors

C12N 2760/18551 ・・・・Methods of production or purification of viral material

C12N 2760/18552 ・・・・・relating to complementing cells and packaging systems for producing virus or viral particles